# Prevalence and determinants of scabies: a global systematic review and meta-analysis

Saptorshi Gupta<sup>1</sup>, Simon Thornley<sup>1</sup>, Arthur Morris<sup>2</sup>, Gerhard Sundborn<sup>3</sup>, Cameron Grant<sup>4</sup>

<sup>1</sup> Section of Biostatistics and Epidemiology, Faculty of Medical and Health Sciences, The University of Auckland, M&HD Building 507, 28 Park Ave, Grafton, Auckland-1023, New Zealand

<sup>2</sup> LabPlus, Auckland City Hospital, Gate 4, Building 31, Auckland City Hospital, Grafton, Auckland 1148

<sup>3</sup> Section of Pacific Health, Faculty of Medical and Health Sciences, The University of Auckland, M&HD Building 507, 28 Park Ave, Grafton, Auckland-1023, New Zealand

<sup>4</sup> Department of Pediatrics, Child and Youth Health, Faculty of Medical and Health Sciences, The University of Auckland, M&HD Building 507, 28 Park Ave, Grafton, Auckland-1023, New Zealand

#### Abstract

#### **Objectives**

Scabies is a neglected skin disease that disproportionately affects people from resource poor and overcrowded countries. Global data on prevalence and risk factors are limited. This article aims to estimate the global burden of scabies and identifies the risks associated with it.

#### Methods

Databases (PubMed, Scopus and Cochrane Reviews) were accessed to identify studies of scabies prevalence published between 2000 and 2024. Results were pooled to estimate prevalence and identify factors which explained between-study heterogeneity. Odds ratios, risk of bias, subgroup analyses and meta-regression were used to describe variation in effect size and heterogeneity based on country-level demographic and economic variables.

#### Results

Seventy studies yielded a pooled prevalence of 11.9% (95% confidence interval [CI] 9.60%-14.7%) with substantial heterogeneity ( $l^2 = 100\%$ ;  $\tau^2 = 1.04$ ). Prevalence was highest in Oceania (17.9%; 95% CI 13.9-22.8) compared to other regions. Pooled risk factors for scabies showed significant associations for demographic and behavioral factors including contact history with household members with itch (odds ratio [OR] 11.3; 95% CI 4.82-26.51;  $l^2 = 96\%$ ; n = 7), lack of soap use (OR 3.41; 95% CI 2.56-4.54;  $l^2 = 44\%$ ; n = 7), bed-sharing (OR 2.64; 95% CI 1.50-4.63;  $l^2 = 76\%$ ; n = 7), sharing of clothes (OR 2.52; 95% CI 1.58-4.03;  $l^2 = 85\%$ ; n = 7), infrequent bathing (OR 2.13; 95% CI 1.41-3.22;  $l^2 = 77\%$ ; n = 6), presence of pets (OR 1.76; 95% CI 1.08-2.87;  $l^2 = 84\%$ ; n = 4) and being a male (OR = 1.19; 95% CI 1.04-1.37;  $l^2 = 83\%$ ; n = 22). Socio-economic factors were not convincingly associated with scabies prevalence.

#### Conclusion

Prevalence of scabies is associated with geographic location and behavioural factors, but not betweencountry socioeconomic status. In addition to mass drug administration, risk factors are identified which may be included in health promotion programmes to reduce scabies prevalence and its sequelae in the long term.

Keywords: scabies, prevalence, risk factors, mass-drug administration

## Introduction

Scabies is a parasitic and contagious disease that affects an estimated 200 million people globally, with a particularly high burden in Asia, Oceania, and Latin America (1). It leads to itchy skin, the clinical manifestations of which are characterised by small inflammatory and pruritic skin papules resembling a mosquito bite.

Scabies occurs more frequently in the young and elderly, and in immunocompromised individuals. Scabies is not benign as it is associated with complications including impetigo, cellulitis and skin abscesses, and post-infectious complications including post-streptococcal glomerulonephritis. Caused by the mite *Sarcoptes scabiei* var. *hominis,* scabies infects about 10% of children in resource-poor areas principally through human skin-to-skin contact.

Over the past decade, substantial efforts have been made by the International Alliance for the Control of Scabies (IACS) to raise the profile of scabies and prioritise control efforts (2). Recent epidemiological evidence has shown increased morbidity and mortality (3) mostly due to secondary bacterial infections occurring following scabies (2,4). Invasive secondary infections with *Streptococcus pyogenes* and *Staphylococcus aureus* (5) can lead to serious invasive bacterial infection and septicaemia. Glomerulonephritis (6) and acute rheumatic fever (7) can occur following *S. pyogenes* infection. The direct discomfort from scabies causes sleep deprivation (8), poor performance at work and reduced quality of life (9). Despite the health impacts and complications that can occur from scabies, there is limited published information about the global prevalence and distribution of the disease. Thus, to determine the prevalence and risks associated with scabies, a meta-analysis at a global scale was conducted.

# Methods

## Objectives and aim

This meta-analysis aimed to review studies describing the burden of scabies and estimate its global prevalence. We also aimed to identify factors associated with prevalence in different population settings.

## Search strategy and identification of studies

A search was conducted using PubMed, Scopus and Cochrane database. Studies published since 2000 were included. All study designs including case-control, cohort and cross-sectional studies were considered. The keywords used for search of relevant articles were 'scabies', 'controlled study', 'major clinical study', 'skin disease', 'prevalence', 'skin defect', 'cross-sectional study', 'risk factor', 'mite', 'contact dermatitis', 'incidence', 'disease association', 'skin examination', 'infection' and 'comparative study'. The reference list of the retrieved articles was also screened for additional articles. The search strategy and number of articles reviewed at each stage is enumerated in **Supplement S1**.

## Inclusion and exclusion criteria

The exclusion and inclusion of studies were conducted according to the latest version of the PRISMA guidelines (10). Studies that clearly reported the prevalence of scabies in the form of absolute number and percentages with 95% confidence intervals in a particular country or region among a specified population were included. Studies that were freely available, published in English and could be retrieved as full-length articles were included.

Studies assessing skin conditions that did not specifically report the number of scabies cases were excluded. Additionally, articles that were published in foreign languages or were available only in subscription format were excluded.

#### Outcome variable

Outcomes selected for pooled analyses were prevalence of scabies infestation and odds ratios associated with the risk of having scabies.

#### Data extraction

Titles and abstract were independently reviewed by two authors (SG and ST). Subsequently studies were selected based on the inclusion and exclusion criteria. The following information was abstracted from each of the selected studies: author, year of publication, study period, prevalence (absolute number), prevalence as a percentage, method of diagnosis, country of study, World Health Organization (WHO) region, United Nations Statistics Division of countries, geographic location, population setting of the study, Gross Domestic Product (GDP) per capita in US\$ of the study country, Gini index, Human Development Index (HDI), average income level of the country, age range of the population studied, the total sample size and different determinants of scabies. Among the included studies, a few were performed to determine the impact of mass drug administration on scabies prevalence (11–18). From these studies, the baseline prevalence data were used for the pooled estimates as these data describe the prevalence among the community without any intervention. The socio-economic indicators, GDP, HDI and Gini index, could only be measured at the country level (19–21).

#### Quality assessment

The quality of each extracted article was assessed with the help of the Joanna Briggs Checklist for Analytical Cross-Sectional, Cohort Studies or Case-Control Studies. In studies that evaluated scabies interventions, we considered baseline prevalence only. Two reviewers (SG and ST) independently assessed risk of bias using percentage scores. A score percentage of 49 or lower was categorized as low quality whereas score percentages ranging from 50 to 69 and 70 or higher were categorized as moderate and high quality respectively. Detailed information regarding the quality of included studies is presented in **Supplementary S2**.

## Statistical analysis

The *meta*, *metafor* and *dmetar* packages of R software (version 4.3.2) (22) were used for analysis (pooling of prevalence and odds ratios), assessment (statistical tests of significance), and visualization. Results were pooled using random effects meta-analysis for primary analyses. Subgroup analyses were conducted to explore the prevalence of scabies infestation based on varying conditions like region, location, method of diagnosis, population setting and income level of the population under consideration. Meta-regression was performed on indicators of the country level socio-economic factors GDP, HDI and Gini index. Odds ratio (OR) with 95% confidence intervals (CI) were calculated separately for demographic and behavioral risk factors like contact history with household member with itch, soap use, frequency of baths, bed sharing, sharing clothes, source of water, presence of pets, location, family size, and gender.

## Assessment of Heterogeneity

The Cochran's Q statistic. Higgin's and Thompson's  $I^2$  and  $\tau^2$  statistics, with an alpha value of 0.05 were used to assess the degree of between-study heterogeneity. A *p*-value less than 0.05 for the Q statistic was used to confirm heterogeneity.  $I^2$  was used to assess heterogeneity, as a measure of the percentage of variability in the effect size which could not be explained by sampling error (23). Values of  $I^2$  equal to 50% or greater was considered 'high'. The  $\tau^2$  statistic was used to measure the degree of between-study variance in the meta-analysis. For  $I^2$  values of greater than 50%, a random effects model was used. A Baujat plot was used to detect potential outliers in the study and

subsequently an influence analysis was used to check the effect of individual studies on pooled results and between-study heterogeneity on a case-by-case basis (24,25).

## Risk of Bias


The Harbord (26) and Peters test (27) were used to assess the risk of this bias in pooled odds ratios (OR). The Harbord test addresses shortcomings of the better-known Egger's test in the case of substantial between-study heterogeneity (28). Similarly, since Egger's test is deemed inappropriate due to its high type-I error when ORs are pooled, especially with large ORs and high between-study heterogeneity, the Peters test was used instead (27). The 'trim and fill' method were used to correct pooled estimates for publication bias if it was found (29).

## Results

## Description of identified studies.

A total of 634 studies were identified. After removing duplicates, studies written in languages other than English, studies published before the year 2000 and non-articles, the titles, and abstracts of 502 studies were screened for relevance. Out of these, 238 studies were assessed for eligibility. In this systematic review and meta-analysis, 70 met the inclusion criteria (**Figure 1**).

Figure 1: Search strategy



All 70 included studies were conducted after 2000. The global pooled prevalence of scabies was determined from studies that included 10,324,381 participants (**Supplementary S3**). The sample size of studies ranged from 118 to 9,057,427 participants. Of the 70 eligible studies, twelve were conducted in Ethiopia (30–41), nine in Fiji (14,42–47), six in the Solomon Islands (13,16,18,48–50), four in Timor-Leste (47,51–53), five in India (11,54–57), three in Ghana (58–60) and Turkey (61–63), two in Australia (15,64), Nigeria (65,66), Malaysia (67,68), France (69,70) and Cameroon (71,72), and one each in Egypt (73), Gambia (74), Morocco (75), Iran (76), Lao (77), Liberia (78), Malawi (12), New Zealand (79), Poland (80), Guinea-Bissau (81), Botswana (82), Togo (83),Samoa (84), Bangladesh (85),Sri Lanka (86), Tanzania (17), United Kingdom (87) and Vanuatu (88). A detailed table of the study characteristics is present in **Supplementary S4**.

#### Prevalence of scabies

Pooled global prevalence was 11.9% (95% CI 9.60%-14.7%). Scabies prevalence ranged widely from 0.4% to 71% (**Figure 2**), with marked variation by WHO region. Highest prevalence was recorded in the Western-Pacific region followed by the African region and the South-east Asian region. Country-level prevalence of scabies is mapped in **Figure 3**, with high prevalence in countries in the Pacific,

South-East Asia, and Africa. Pacific countries like Timor-Lester, Vanautu, Fiji and the Solomon Islands, marked in dark red, showed the highest pooled prevalence. Factors including different methods of diagnosis, study period, country and area under consideration explained some of the high heterogeneity in prevalence ( $l^2 = 100\%$ ;  $\tau^2 = 1.04$ ; 95% CI: 0.75 – 1.53). Due to this high heterogeneity, a random effects model was used to compute the summary statistic. The forest plot shows the highest pooled prevalence in the Western-Pacific (17.8%; 95% CI: 13.9-22.5%), followed by Africa (12.9%; 95% CI: 9.6%-17.1%) and South-East Asia (11.4%; 95% CI: 6.4%-19.5%). The lowest prevalence region was the Eastern Mediterranean. Noticeably higher numbers of studies were published from high prevalence countries compared to low.

## Outliers and Sensitivity Analysis


The influence analysis, sensitivity analysis and Baujat plot identified four potential outliers (**Supplements S5**, **S6**, and **S7**). After removal of these studies, the pooled prevalence of scabies was 11.8% (95% CI: 9.71% to 14.26%). The sensitivity analysis also confirmed that the high heterogeneity was not dependent on a single study. Analyses hereafter have been conducted with these outliers removed.

#### Subgroup Analysis

Subgroup analyses were completed after taking into consideration the method of diagnosis, WHO Region, United Regions Statistics Division (UNSD) of countries, geographic location, population settings and income status. Only region and method of diagnosis were significantly associated with prevalence. A high prevalence of 19.5% (95% CI 13.4%-27.5%) was found among studies that used the IACS criteria to diagnose scabies suggesting a higher sensitivity of the clinical definition (**Table 1**). Oceania, in the Western Pacific Region, had the highest prevalence of scabies cases. Studies that enrolled samples from specific settings, e.g., hospitals or old-age homes reported higher prevalences (13.10%; 95% CI 8.28-20.1) compared to studies performed in community settings (12.3%; 95% CI 9.63-15.6). Upper middle-income countries showed the highest pooled prevalence of scabies (15.2%; 95% CI 10.7-21.1) compared to lower-middle (12.6%; 95% CI 8.67-17.8), low (9.95%; 95% CI 7.60-12.9), and high-income countries (7.87%; 95% CI 4.96-12.3), although these differences were not statistically significant.

Figure 2: Forest plot showing pooled global scabies prevalence

(CMR) Kouotou et al (ETH) Haile et al (ETH) Melese et al (ETH) Ararsa et al (BWA) Rainer et al	200 379000				
(ETH) Enblale et al (CMR) Kouotou et al (ETH) Haile et al (ETH) Melese et al (ETH) Ararsa et al (BWA) Rainer et al					
(CMR) Kouotou et al (ETH) Haile et al (ETH) Melese et al (ETH) Ararsa et al (BWA) Rainer et al	319000	283 1125770		0.707 [0.650; 0.759] 0.337 [0.336: 0.338]	
(ETH) Haile et al (ETH) Melese et al (ETH) Ararsa et al (BWA) Rainer et al	242	755		0.321 [0.287; 0.355]	
(ETH) Melese et al (ETH) Ararsa et al (BWA) Rainer et al	139	583		0.238 [0.204; 0.275]	
(BWA) Rainer et al	203	942		0.215 [0.190; 0.243]	
(BWA) Rainer et al	88	457	1.4%	0.193 [0.157; 0.232]	
	78	429		0.182 [0.146; 0.222]	
(CMR) Kouotou et al	338	1902		0.178 [0.161; 0.196]	
(GMB) Armitage et al (MWI) Casas et al	229 2392	1441 15487		0.159 [0.140; 0.179] 0.154 [0.149; 0.160]	
(ETH) Yirgu et al	192	1437		0.134 [0.116; 0.152]	
(GHA) Kaburi et al	92	823		0.112 [0.091; 0.135]	<b>a</b>
(ETH) Sara et al	4532	41278		0.110 [0.107; 0.113]	
(ETH) Misganaw et al	92	850		0.108 [0.088; 0.131]	
(NGA) Kalu et al	42	400		0.105 [0.077; 0.139]	
(GHA) Birjandi et al (ETH) Enbiale et al	286 875690	2766 9057427		0.103 [0.092; 0.115] 0.097 [0.097; 0.097]	
(LBR) Collinson et al	123	1318		0.093 [0.078; 0.110]	
(ETH) Dagne et al	46	494		0.093 [0.069; 0.122]	
(ETH) Bogino et al	37	418	1.4%	0.089 [0.063; 0.120]	-
(TGO) Saka et al	86	1401		0.061 [0.049; 0.075]	
(ETH) Walker et al	19	343		0.055 [0.034; 0.085]	
(ETH) Amare & Lindtjorn (GNB) Marks et al	46 56	861 1062		0.053 [0.039; 0.071]	
(GNB) Marks et al (NGA) Ogunbiyi et al	50	1062		0.053 [0.040; 0.068] 0.047 [0.035; 0.061]	
(TZA) Martin et al	101	2269		0.045 [0.036; 0.054]	
Total (95% CI)		10262262	37.6%	0.129 [0.096; 0.171]	•
Heterogeneity; Teu <sup>2</sup> = 0.7421	t; Chi <sup>2</sup> = 4	03541.52,	it.= 25 (P	$= 0), t^2 = 100\%$	
WHO = Eastern Mediterr					
(EGY) Hegab et al	92	2104		0.044 [0.035; 0.053]	
(IRN) Dehkordi et al	15	480		0.031 [0.018; 0.051]	
(MAR) Laraqui et al Total (95% CI)	11	1102		0.010 [0.005; 0.018]	
Heterogeneity: Tau <sup>2</sup> = 0.5426	5. Chi <sup>2</sup> = 2				
WHO = European Regior (TUR) Ural et al	41	376	1.4%	0.109 [0.079; 0.145]	-
(GBR) Hewitt et al	39	363		0.107 [0.078; 0.144]	
(POL) Bartosik et al	32	322		0.099 [0.069; 0.137]	
(FRA) Rigal et al	10	142		0.070 [0.034; 0.126]	-
(FRA) Philippe et al	27	930		0.029 [0.019; 0.042]	
(TUR) Inanir et al	17	785		0.022 [0.013; 0.034]	
(TUR) Ciftci et al Total (95% CI)	5	1134 4052		0.004 [0.001; 0.010]	
Heterogeneity: Tau <sup>2</sup> = 1.3750	i; Ghi <sup>2</sup> = 1				-
AUX - Western Parties I	the set of a				
WHO = Western Pacific F (SLB) Osti et al	176	324	1.4%	0.543 [0.487; 0.598]	-
(FJI) Romani et al	746	2051		0.364 [0.343, 0.385]	
(FJI) Haar et al	242	760	1.5%	0.318 [0.285; 0.353]	
(MYS) Zayyid et al	37	120		0.308 [0.227; 0.399]	
(VUT) Callum et al (FJI) Romani et al	563	1879		0.300 [0.279; 0.321]	
(FJI) Steer et al	2564 105	10887		0.236 [0.228; 0.244] 0.230 [0.192; 0.271]	
(SLB) Mason et al	366	1908		0.192 [0.174; 0.210]	
(SLB) Marks et al	261	1399		0.187 [0.166; 0.208]	-
(FJI) Steer et al	640	3462	1.5%	0.185 [0.172; 0.198]	-
(AUS) Tasani et al	84	508		0.165 [0.134; 0.201]	
(SLB) Lake et al	787	5239		0.150 [0.141, 0.160]	
(WSM) Taiaroa et al (FJI) Tsoi et al	120 470	833 3351		0.144 [0.121; 0.170] 0.140 [0.129; 0.152]	ā
(FJI) Steer et al	63	451		0.140 [0.109; 0.152]	
(FIJ) Hardy et al	513	3812		0.135 [0.124; 0.146]	
(FJI) Hardy et al	513	3812	1.5%	0.135 [0.124; 0.146]	
(SLB) Marks et al	75	638		0.118 [0.094; 0.145]	-
(NZL) Thornley et al (SLB) Coscione et al	16 12	145 118		0.110 [0.064; 0.173] 0.102 [0.054; 0.171]	1
(MYS) Yap et al	76	944		0.081 [0.064; 0.100]	
(AUS) Keams et al	42	1002		0.042 [0.030; 0.056]	
Total (95% Cl)		44100		0.178 [0.139; 0.225]	•
Heterogeneity: Teu <sup>2</sup> = 0.4808	I, Chille (	424.77, 01	= 21 (b ×	$0.01$ ); $1_{c} = 00.10$	
WHO = South-East Asiar					
(BAN) Hasan et al	317	935		0.339 [0.309; 0.370]	
(TLS) Tsoi et al (TLS) Matthews of al	321	951		0.338 [0.308; 0.369]	
(TLS) Matthews et al (TLS) Korte et al	348 312	1043 1396		0.334 [0.305, 0.363] 0.223 [0.202, 0.246]	
(TLS) Santos et al	266	1535		0.173 [0.155; 0.193]	
(IND) Burman et al	44	400		0.110 [0.081: 0.145]	
(IND) Behera et al	92	1094		0.084 [0.068; 0.102]	
(IND) Devidas et al	18	210		0.076 [0.044; 0.121]	
(LAO) Wootton et al	16	340		0.047 [0.027; 0.075]	
(IND) Grills et al (IND) Satyamanasa et al	54 43	1172		0.046 [0.035; 0.060] 0.043 [0.031; 0.057]	
(IND) Satyamanasa et al (LKA) Gunathilaka et al	43	205		0.043 [0.031; 0.057]	
Total (95% CI)		10281	16.9%	0.114 [0.064; 0.195]	+
Heterogeneity: Tau <sup>2</sup> = 1.2142	2. Chi <sup>2</sup> = 1	71.11. df =	11 (P<0	$(01)$ , $t^2 = 99\%$	
Total (95% CI)		10324381	100.0%	0.119 [0.096; 0.147]	•



#### Table 1: Scabies prevalence by subgroup.

	Studies (n=66)	Prevalence	95% CI	I <sup>2</sup>	<i>P</i> -value for subgroup difference
Method of Diagnosis					0.005
IACS	12	19.48%	13.4-27.5	98.7%	
IMCI	6	16.04%	10.3-24.2	98.8%	
Traditional Method (Burrows, Pruritus)	48	9.94%	7.90-12.4	98.6%	
WHO Region					< 0.001
Western Pacific Region	22	17.76%	13.9-22.5	98.5%	
South-East Asian Region	12	11.40%	6.39-19.5	98.6%	
African Region	23	11.20%	8.88-14.1	97.9%	
European Region	6	6.23%	3.51-10.8	92.6%	
Eastern Mediterranean Region	3	2.48%	1.05-5.74	91.1%	
UNSD of Countries					0.001
Oceania	20	17.90%	13.9-22.8	98.6%	
Asia	17	10.11%	6.19-16.1	98.5%	
Africa	25	9.95%	7.48-13.1	98.0%	
Europe	4	6.91%	3.81-12.2	91.2%	
Location					0.77
Urban and rural	19	13.20%	8.18-20.5	99.2%	
Rural	29	11.50%	8.78-14.9	98.6%	
Urban	18	10.80%	7.99-14.4	97.0%	
Population Setting					0.71
Other*	11	13.10%	8.28-20.1	97.6%	
Community	33	12.32%	9.63-15.6	99.0%	
School	22	10.43%	6.94-15.4	98.6%	
Income Status					0.09
Upper middle-income	14	15.20%	10.7-21.1	98.6%	
Lower middle income	28	12.60%	8.67-17.8	98.6%	

<b>X 1 00 X</b> 1 1 1 1 1 1		a 11 m (at t	13.6	0.001.11.11	1.7
High income	7	7.87%	4.96-12.3	94.1%	
Low income	17	9.95%	7.60-12.9	97.8%	

IACS: International Alliance for the Control of Scabies; IMCI: Integrated Management of Childhood Illness; WHO: World Health Organization; UNSD: United Nations Statistics Division.

\* Includes studies conducted in childcare centres, welfare homes, clinics and hospitals

## Factors associated with scabies.

Separate meta-regression models showed no association of GDP, HDI or the Gini index with scabies infestation (**Supplement S8**).

#### Behavioral and demographic Factors

Association of scabies status was found to be significant with the following behavioral factors – contact history with household members with itch (OR 11.3; 95% CI 4.82-26.51;  $l^2 = 96\%$ ; n=7), non-use of soap (OR 3.41; 95% CI 2.56-4.54;  $l^2 = 44\%$ ; n=7), bed sharing (OR 2.64; 95% CI 1.50-4.63;  $l^2 = 76\%$ ; n=7), cloth sharing (OR 2.52; 95% CI 1.58-4.03;  $l^2 = 85\%$ ; n=7), infrequent bathing (OR 2.13; 95% CI 1.41-3.22;  $l^2 = 77\%$ ; n=6), presence of pets (OR 1.76; 95% CI 1.08-2.87;  $l^2 = 84\%$ ; n=4) and gender (OR = 1.19; 95% CI 1.04-1.37;  $l^2 = 83\%$ ; n=22). No significant association was observed between scabies and location (OR 1.27; 95% CI 0.64-2.53;  $l^2 = 98\%$ ; n=6), use of 'raw' sources of water obtained from unprotected dug wells, unprotected springs, carts with small tank/drum and tanker trucks (89) (OR 1.57; 95% CI 0.60-4.06;  $l^2 = 93\%$ ; n=4), and family size (OR = 1.33; 95% CI 0.93-1.91;  $l^2 = 70\%$ ; n=7). Forest plots of these behavioral and demographic factors are illustrated in **Figure 4**.

## Publication bias

Meta-analyses of risk factors showed no evidence of publication bias (Supplement S9).

95% CI			Soap			Odds Ratio			ids Ratio
	Events	Total I	Events	Total	Weight	MH, Random, 95	% CI	MH, Rar	ndom, 95%
(ETH) Bogino et al	6	15	31	403	5.7%	8.00 [2.67; 23.	94]		+
(ETH) Ararsa et al	80		8	128	10.1%	4.82 [2.26; 10.			-
(ETH) Dagne et al	15		31	431	11.7%	4.03 (2.03; 8.0			
(ETH) Misganaw et al (ETH) Haile et al	51 68		41 37	609 286	19.1% 18.7%	3.72 (2.39; 5.) 3.69 (2.34; 5.)			
(CMR) Kouotou et al	80			1672	25.3%	2.92 [2.16; 3.9			1
(BAN) Hasan et al	10		307	909	9.4%	1.23 [0.55; 2.]			-
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0	0607-0	1096 h <sup>2</sup> = 10			100.0%		54]		•
reactogenery, ray = o		a - 10.	10, 01 = 1	(r = 0	. 10), 1 =			0.1 0.5	512
CI									
Study			Doesn'i			Odds Rati MH, Random, S			Idds Ratio andom, 95%
(IRN) Dehkordi et al	2.000	9 29				33.37 [10.82; 1		Bin, N	andom, 99%
(EGY) Hegab et al		1 721		1383		2.49 [ 1.63; 3			
(GHA) Birjandi et al		6 639		2127					
(CMR) Kouotou et al	22	2 1109	116	793	18.5%	1.46 [ 1.14;	1.87]		-
(ETH) Haile et al		8 32							-
(ETH) Amare & Lindtjor		4 346							
(ETH) Bogino et al		7 20	30	398	10.4%	6.61 [2.45; 1	7.80]		
Total (95% CI)		2896		6234	100.0%	2.52 [ 1.58;	4.031		
Heterogeneity: Tau <sup>2</sup> = 0.2	2944; Chi						1	1	-
							0.0	0.1	1 1
	Higher	r Size	Lesser	Size		Odds Ratio		Ode	ds Ratio
Study					Neight I	MH, Random, 95	% CI		dom, 95% (
					· ·				1
(IRN) Dehkordi et al	11	221	4	259	6.8%	3.34 [1.05; 10.6			
(ETH) Sara et al	47	119	8	46	10.1%	3.10 [1.33; 7.2			
(ETH) Yirgu et al (GHA) Birjacci et al	122	730 2334	70 37	707 432	19.5%	1.83 [1.33; 2.5			
(GHA) Birjandi et al (TUR) Ural et al			22		18.6% 13.1%	1.27 [0.89; 1.8 0.91 [0.47; 1.7		_	
(WSM) Taiaroa et al			14		13.1%	0.88 [0.48; 1.6			-
(ETH) Haile et al	51		88		18.0%	0.80 [0.54; 1.1		-	-
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 1	0 1474-0	4570			100.0%	1.33 [0.93; 1.9	1		•
neterogeneity: rau" = (	u, 14/4; C	vat = 19.	.ca, di =	n (h, < )	0.01); F =	1975	0.1	0.5	1 2
Study		Rural Total E		rban Total N	Neight I	Odds Ratio MH, Random, 95	% CI		ds Ratio Idom, 95% C
	100.00	10000	2.23	1000	-	1.000000000	0	,	
(TUR) Ural et al (ETH) Dagne et al	21 31	97 257	20	279 237	15.3% 15.4%	3.58 [1.84; 6.9 2.03 [1.07; 3.8			
(FJI) Steer et al	376	1541	264		17.6%	2.03 [1.07, 3.8			
(EGY) Hegab et al		1242	28		16.6%	1.62 [1.03; 2.5			-
(FJI) Romani et al	1611	6304	953		17.8%	1.31 [1.19; 1.4	3]		
(GHA) Birjandi et al		1595	227		17.3%	0.16 [0.12; 0.2		5	
Total (ASH CD		11030	3	-	00.04	1.27 [0.64; 2.5	11	<ul> <li>25</li> </ul>	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = (		11036 bi <sup>2</sup> = 22					21	<b></b>	T
neterogenety, 140 =	e.0830, C	-1 - 10	e. ev, Gl *		20171			0.2 0.5	1 2
0	Unimpr		Impro			Odds Ratio			is Ratio
	Events '	Total E	vents T	otal V		IH, Random, 95	9996 39		ds Ratio dom, 95% C
(ETH) Sara et al	Events 27	Total E	vents T	otal V	24.0%	IH, Random, 95 3.12 (1.57; 6.20	1		
(ETH) Sara et al (TUR) Ural et al	Events 27 12	53 65	28 29	otal V 112 311	24.0% 23.6%	1H, Random, 95 3.12 (1.57; 6.20 2.20 (1.06; 4.55	1		
(ETH) Sara et al (TUR) Ural et al (ETH) Haile et al	27 12 52	53 65 151	28 29 87	otal V 112 311 432	24.0% 23.6% 26.1%	1H, Random, 95 3.12 [1.57; 6.20 2.20 [1.06; 4.59 2.08 [1.38; 3.14	9		
(ETH) Sara et al (TUR) Ural et al	27 12 52	53 65	28 29 87	otal V 112 311 432	24.0% 23.6%	1H, Random, 95 3.12 (1.57; 6.20 2.20 (1.06; 4.55	9		

$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{l} 15.0\%. \\ 314.5\%. \\ 14.5\%. \\ 15.5\%. \\ 15.5\%. \\ 15.5\%. \\ 15.5\%. \\ 15.5\%. \\ 10.01; \ l^{2} = 0 \\ 10.01; \ l^{2} = 0 \\ 18.8\%. \\ 10.01; \ l^{2} = 5.6\%. \\ 18.8\%. \\ 15.5\%. \\ 15.5\%. \\ 100.0\%. \\ 15.5\%. \\ 100.0\%. \\ 15.8\%. \\ 100.0\%. \\ 10.0\%.$	Odds Ratio MH, Random, 9 7 60 (2 26; 25; 3 32 (2 27; 4; 6) 3 28 (2 27; 4; 6) 3 28 (2 27; 4; 6) 3 26 (1 15; 6) 2 55 (1 16; 5) 1 7.74 (2 22; 1) 3 05 (1 6; 4) 5 0 0 dds Ratio H, Random, 957 3 03 (1 40; 6 53 1.97 (1 34; 240 1.61 (103; 25) 1.02 (0.66; 1.51) 2 13 (1 41; 3 22	.42]     .42]       .62]     .01       .51]     .0.01       .51]     .0.01       .60]     .61       .61]     .62]       .63]     .0.1       .63]     .0.1       .63]     .0.1       .63]     .0.1       .63]     .0.1       .63]     .0.1       .63]     .0.1       .63]     .0.1       .63]     .0.1       .64]     .1       .65]     .1       .63]     .1       .64]     .1       .65]     .1       .63]     .1       .64]     .1       .65]     .1       .65]     .1       .65]     .1       .65]     .1       .65]     .1       .65]     .1       .75]     .1       .76]     .1       .77]     .2       .78]     .1       .79]     .1       .71]     .1       .72]     .1       .73]     .1       .74]     .1       .75]     .1       .76]     .1       .77]     .1       .76]     .1 <tr< th=""></tr<>
	14.5% 15.5% 15.5% 15.5% 14.1% 00.0% 14.1% 00.0% 14.1% 00.0% 14.1% 00.0% 14.1% 00.0% 14.1% 00.0% 15.5% 15.3% 5.6% 15.3% 10.0% 15.3% 15.	4 63 [ 2.48; 86 4 4 50 ] 3.36; 60 33, 60 33, 44 50 33, 60 33, 44 50 33, 60 0 3.44 [ 1.67; 7.1 11.30 [ 4.82; 26 , 96%] Odds Ratio MH, Random, 99 7 60 [ 2.62 , 51 , 43 3] 2.74; 61 , 43 3] 2.74; 61 , 43 3] 2.74; 61 , 43 3] 2.74; 61 , 43 3] 2.74; 61 , 45 , 45 , 45 , 45 , 45 , 45 , 45 , 4	S2] S2] S2] S2] S2] S2] S2] S3] S51 S55 CI MH, Random, 9 S51 S51 Odds Ratio S56 CI MH, Random, 9 S51 Odds Ratio S56 CI MH, Random, 9 S51 CI MH, Random, 9 S51 CI S51
7 565 1 8 1107 1 9 113 1 9 113 1 9 113 1 9 113 1 1 = 6 (P < 0. 1 = 6 (P < 0. 1 = 6 (P < 0. 1 = 5 (P < 0.01 1 = 5 (P < 0.01) (P < 0.01 1 = 5 (P < 0.01) (P	15.5% 15.5% 15.5% 15.5% 10.7% 15.5% 10.01; i <sup>2</sup> = 5 10.7% 10.7% 15.5% 100.0% 15.5% 100.0% 15.5% 100.0% 15.5% 100.0% 15.5% 100.0% 15.5% 100.0% 15.5% 10.7% 10.6%	A 50 [ 338; 60 377 [ 293; 48 377 [ 293; 48 377 [ 293; 48 377 [ 293; 48 377 [ 293; 44 ] 167; 7. 1 1.30 [ 4.82; 26.] 99% Odds Ratio MH, Random, 92 7.60 [ 26; 55 43 32 [ 21; 41 33 [ 21, 46 ] 135; 61 ] 238 [ 221; 41 ] 306 [ 135; 61 ] 255 [ 11, 65 ] (225 ] 11, 65 ] (225 ] 11, 65 ] (225 ] 11, 65 ] (225 ] 11, 65 ] (225 ] 11, 65 ] (225 ] (216 ] 11, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] 13, 74 ] (22 ] (21	D1]         0           64]         0           0.01         0.1           0.01         0.1           0.01         0.1           0.01         0.1           0.01         0.1           0.01         0.1           0.01         0.1           0.1         0.5           0.1         0.5           0.1         0.5           0.1         0.5           0.1         0.5           0.1         0.5           0.1         0.5           0.1         0.5           0.2         0.5           0.2         0.5           0.2         0.5           0.1         0.5           0.2         0.5           0.1         0.5           0.2         0.5           0.5         0.5           0.5         0.5           0.5         0.5           0.5         0.5           0.5         0.5           0.5         0.5
9 113 1 19 113 1 1 = 6 (P < 0. art share tis Total 20 39 2561 303 1787 7 296 304 31 243 3063 31 243 307 243 307 244 307 244	14.1% 00.0% 1 10.7% 10.0% 10.7% 10.7% 10.7% 10.0% 10.7% 10.7% 10.0% 10.7% 10.7% 10.0% 10.7% 10.0% 10.7% 10.8% 10.0% 10.7% 10.8% 10.0% 10.6%	3.44 [ 1.67; 7.1           11.30 [ 4.82; 26.           96%           Odds Ratio           MH, Random, 9;           7.60 [ 2.62; 53.           3.28 [ 2.71; 4].           3.06 [ 1.55; 61.           3.28 [ 2.71; 4].           3.06 [ 1.55; 61.           3.28 [ 2.71; 4].           3.06 [ 1.55; 61.           2.56 [ 1.16; 6].           2.56 [ 1.16; 6].           MH, Random, 95           3.95 [ 1.84; 8.44           3.05 [ 1.02; 1.02; 1.10; 4].           1.74 [ 0.22; 1.3].           3.05 [ 1.16; 6].           1.75 [ 1.47; 3.22]           0.26 [ 1.10; 2.52; 1.11; 6].           3.05 [ 1.16; 6].           1.02 [ 0.69; 1.51]           2.13 [ 1.41; 3.22]           0.16; 1 [ 1.00; 2.52; 1].           1.01 [ 1.65; 0.83; 1].           1.02 [ 0.69; 1.51]           2.23 [ 1.15; 4].           2.23 [ 1.15; 4].           3.28 [ 1.00; 2.52]           1.16; 6] [ 0.83; 1].           1.23 [ 1.00; 14]; 5].           1.38 [ 1.04; 18]; 1.33 [ 1.04; 18].           1.38 [ 1.04; 18]; 1.33 [ 1.04; 18].           1.38 [ 1.04; 18]; 1.33 [ 1.04; 18]; 1.33 [ 1.34; 1.33 [ 1.34; 1.33 [ 1.34; 1.35].	12] 0.01 0.1 1 1 0.01 0.1 1 1 0 Odds Ratio 60] 60] 60] 61] 63] 0.1 0.5 1 2 0.2 0.5 1 2 0.5 1 2 0.
3917 10           f = 6 (P < 0.	$\begin{array}{llllllllllllllllllllllllllllllllllll$	11.30 [ 4.82; 26. 96% Odds Ratio MH, Random, 99 7.60 [ 26; 25; 1.74 [ 0.22; 13] 0.56 [ 0.26; 15] 1.74 [ 0.22; 13] 0.56 [ 0.26; 15] 1.74 [ 0.22; 13] 0.56 [ 0.26; 15] 2.55 [ 11; 6; 12] 2.55 [ 11; 6; 12] 2.55 [ 11; 6; 13] 2.22 [ 21; 8; 47] 0.30 [ 14; 8; 63] 3.95 [ 16; 43; 63] 3.95 [ 16; 43; 63] 3.03 [ 14; 6; 63] 1.02 [ 0.69; 15] 2.13 [ 1,41; 3.22 7% Odds Ratio MH, Random, 95 2.23 [ 11; 5; 43] 2.13 [ 1,41; 3.22 7%	51) 0.01 0.1 1 1 5% Cl MH, Random, 9 60] 64] 63] 64] 63] 0.1 0.5 1 2 % Cl MH, Random, 95 9] 51 0.1 0.5 1 2 % Cl MH, Random, 95 9] 51 02 0.5 1 2 % Cl MH, Random, 95 9] 51 02 0.5 1 2 % Cl MH, Random, 95 9] 51 02 0.5 1 2 % Cl MH, Random, 95 9] 51 10 10 10 10 10 10 10 10 10 1
rt share rts Total 20 39 32 561 33 1787 7 296 33 1 243 3063 31 243 31 243 3063 31 243 31 243 32 251 15 2965 17 222 17 5 32 255 33 444 35 265 17 222 17 5 32 47 33 488 17 222 17 5 32 47 33 488 17 222 17 5 32 47 33 488 17 222 17 37 33 488 17 27 17 222 17 37 17 272 17 37 17 272 17 37 17 272 17 37 17 272 17 37 17 37 17 37 17 37 17 37 17 31 17 4 17 4 17 4 17 4 17 4 17 1 17 1	Weight I 10.7% 18.8% 19.4% 5.6% 15.5% Veight M 12.8% 10.0% 15.5% 10.0% 15.5% 10.0% 15.5% 10.0% 10.7% 10.7% 10.7% 10.7% 10.7% 10.8% 00.0% 11.7% 10.7% 10.7% 10.8% 00.0% 11.7% 10.7% 10.7% 10.7% 10.8% 00.0% 11.7% 10.7% 10.7% 10.8% 10.7% 10.8% 10.7% 10.8% 10.7% 10.8% 10.7% 10.8% 10.8% 10.7% 10.8% 10.8% 10.7% 10.8% 10.7% 10.8% 10.8% 10.7% 10.8% 10.7% 10.7% 10.8% 10.7% 10.6% 10.	Odds Ratio MH, Random, 99 7.60 [26, 25, 338 [2.24, 0] 3.08 [2.24, 4] 3.06 [1.35, 61 2.25 [1.16, 5] 1.74 [0.22, 13, 0.56 [0.26, 1] 2.64 [1.50, 4] 5 0.56 [0.26, 1] 2.64 [1.50, 4] 5 0.55 [1.84, 846 3.22 [2.18, 4.846 3.22 [2.18, 4.75 3.03 [1.46, 6.53 1.02 [0.69, 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, 95 2.23 [1.15, 4.3] 2.13 [1.41; 3.22 7%	0.01 0.1 1 1 o Odds Ratio (60] (61] (62] (63] (63] (63] (63] (63] (64] (71) (73) (74) (75) (7
	10.7% 10.8% 19.4% 5.6% 15.5% 15.5% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.7% 13.8% 00.0% 11); i <sup>+</sup> = 77 7 7 8 8 8 8 8 8 5.6% 15.5% 1	MH, Random, 95 7.60 [2.26; 25: 4.33 [2.74; 61 3.28 [2.74; 41 3.06 [1.35; 61 2.55 [1.16; 51 7.74 [0.22; 31, 3.05 [0.26; 1: 2.64 [1.50; 4] 5 Odds Ratio H, Random, 95 3.95 [1.84; 8.45 3.03 [1.46; 63 3.03 [1.46; 1.37] 2.13 [1.41; 3.22 7%	Odds Ratio           65% CI         MH, Random, 9           60]
	10.7% 10.8% 19.4% 5.6% 15.5% 15.5% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.7% 13.8% 00.0% 11); i <sup>+</sup> = 77 7 7 8 8 8 8 8 8 5.6% 15.5% 1	MH, Random, 95 7.60 [2.26; 25: 4.33 [2.74; 61 3.28 [2.74; 41 3.06 [1.35; 61 2.55 [1.16; 51 7.74 [0.22; 31, 3.05 [0.26; 1: 2.64 [1.50; 4] 5 Odds Ratio H, Random, 95 3.95 [1.84; 8.45 3.03 [1.46; 63 3.03 [1.46; 1.37] 2.13 [1.41; 3.22 7%	5% CI MH, Random, 9 60] 64] 55] 55] 55] 65] 65] 65] 66] 7% CI MH, Random, 95 9] 67% CI MH, Random, 95 70% CI MH, Rand
20 39 32 561 39 1787 7 256 8 83 1 54 31 243 3063 3 6 (P < 0.01 5 261 2 9 814 1 5 261 1 5 266 1 9 814 1 5 5 26 1 5 266 1 17 222 103 15 378 3 3 468 11 77 222 1103 15 378 3 3 469 9 1977 7 51 4 751 2 7 51 499 9 7 51 499 9 7 51 499 9 7 51 41770	10.7% 10.8% 19.4% 5.6% 15.5% 15.5% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.7% 13.8% 00.0% 11); i <sup>+</sup> = 77 7 7 8 8 8 8 8 8 5.6% 15.5% 1	7 60 (2 26; 25; 3 32 (2 7, 6) 3 28 (2 21; 4) 3 28 (2 21; 4) 3 28 (2 21; 4) 3 26 (1 35; 6) 2 55 (1 16; 54) 1.74 (0 22; 13, 0 56 (0 26; 1) 2.54 (1.50; 4) 5 3 95 (1 84; 8, 44 3 22 (2 16; 4) 77 (1 34; 20) 1.02 (0.69; 1.51) 2.13 (1 41; 3.22 7% Odds Ratio MH, Random, 95 2.23 (1 15; 4) 2.13 (1 41; 3.22 7% Odds Ratio MH, Random, 95 2.23 (1 15; 4) 2.13 (1 41; 3.22 7% Odds Ratio MH, Random, 95 2.23 (1 15; 4) 2.13 (1 41; 3.22 7% Odds Ratio MH, Random, 95 2.23 (1 15; 4) 2.13 (1 41; 3.22 7% Odds Ratio MH, Random, 95 2.23 (1 15; 4) 2.13 (1 41; 3.22 7% Odds Ratio MH, Random, 95 2.23 (1 15; 4) 2.23 (1 10; 4) 2.24 (1 10; 4) 2.25 (1	60] 64] 87] 90] 51] 17] 63] 0.1 0.5 1 2 0.2 0.5 1 2 0.48 0.1 0.5 1 2 0.2 0.5 1 2 0.48 0.1 0.5 1 2 0.2 0.5 1 2 0.5 0 0.5 0
32 561 33 1787 7 296 8 83 31 243 3063 3 243 3063 3 243 3063 3 243 3063 6 (P < 0.01 15 2 0783 1 5 266 1 5 266 1 5 266 1 5 266 1 5 266 1 7 222 1 5 378 3 3 3 468 1 7 222 1 5 378 3 3 468 1 7 273 4 7 3 4 7 7 4 7 4 7 7 4 4 7 7 4 7 7 4 4 7 7 7 4 4 7 7 7 4 4 7 7 7 4 7 7 4 4 7 7 7 4 7 7 4 4 7 7 7 4 7 7 7 4 7 7 7 4 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	18.8% 19.4% 19.4% 14.7% 15.3% 15.5% 15.5% 100.0% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 13.9% 13.9% 13.9% 14.7% 14.7% 15.3% 15.5% 5.6% 5.4% 6.3% 5.3% 6.6%	4 33 [274; 61, 328 [221; 41, 328 [221; 41, 326 [135; 62], 556 [136; 51, 74 [022; 13], 556 [026; 14], 566 [026; 14], 2.64 [1.50; 4J], 6 Odds Ratio H, Random, 957 3.95 [1.84; 8.46 3.02 [1.84; 8.46 3.02 [1.84; 8.46 3.02 [1.84; 8.47 3.05 [1.84; 8.47 3.05 [1.84; 8.47 3.05 [1.84; 8.46 3.02 [1.84; 8.47 3.05 [1.84; 8.47] 3.05	84] 87] 90] 51] 448] 0.1 0.5 1 2 0.1 0.5 1 2 0.1 0.5 1 2 0.1 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.3 0 0.4 0 0.1 0.5 1 2 0.1 0.5 1 2 0.1 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.3 0 0.1 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.3 0 0.1 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.3 0 0.4 0 0.1 0.5 1 2 0.2 0.5 1 2 0.5 0 0 0.1 0.5 1 2 0.2 0.5 1 2 0.1 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.3 0 0.1 0.5 1 2 0.2 0.5 1 2 0.4 0 0.1 0.5 1 2 0.5 0 0 0.2 0.5 1 2 0.5 0 0 0.1 0.5 1 2 0.5 0 0 0.2 0.5 1 2 0.5 0 0 0.5 0 0 0.1 0.5 1 2 0.5 0 0 0.2 0.5 1 2 0.5 0 0 0.5 0 0
393         1787         296         8         3           7         296         8         3         1         54           31         1         54         3         1         54           31         243         3         3         66         6         6         6         6         6         6         6         6         6         6         6         6         6         6         6         7         6         7         6         6         7         5         1         6         6         7         6         6         7         5         1         5         2         6         1         5         2         6         1         5         2         6         1         1         5         2         6         1         1         3         3         3         3         3         3         3         3         3         3         4         3	19.4%; 14.7%; 15.3%; 15.5%; 15.5%; 100.0%; 15.5%; 100.0%; 12.7%; 18.8%; 00.0%; 12.7%; 18.8%; 00.0%; 101; 1 <sup>2</sup> = 77 18.8%; 00.0%; 2.7%; 5.6%; 5.6%; 5.5%; 6.5%; 6.3%; 6.6%; 6.6%; 6.6%;	328 [221; 4] 306 [135; 6] 255 [118; 5] 174 [022; 13, 0.56 [0.26; 1] 2.64 [1.50; 4] 5 Odds Ratio H, Random, 957 395 [184; 8-46 322 [218; 475 303 [146; 53 1.02 [0.69; 1.51 2.13 [1.41; 3.22 7% Odds Ratio H, Random, 95 2.23 [1.15; 4] 2.13 [1.41; 3.22 7% Odds Ratio H, Random, 95 2.23 [1.15; 4] 2.13 [1.41; 3.22 7%	87] 93] 51] 48] 0.1 0.5 1 2 0.1 0.5 1 2 0.1 0.5 1 2 0.1 0.5 1 2 0.2 0.5 1 2 0.3 0 0.1 0.5 1 2 0.1 0.5 1 2 0.2 0.5 1 2 0.1 0.5 1 2 0.2 0.5 1 2 0.1 0.5 1 2 0.2 0.5 1 2 0.1 0.5 1 2 0.5 1 2
7 2 26 8 83 1 54 31 243 3063 6 (P < 0.01	14.7% 15.3% 5.6% 15.5% 100.0% 15.5% 100.0% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 12.8% 00.0% 01; i <sup>2</sup> = 779 Weight M 2.7% 5.6% 6.6% 15.5% 15.	3 06 [135, 61 255 [118, 51 1.74 [022, 13, 61 0.56 [0.26, 1. 2.64 [1.50; 4.] 6 0dds Ratio H, Random, 95 3.95 [1.84, 8.46 3.03 [146, 63 3.05 [1.84, 8.46 3.03 [146, 63 3.02 [218, 147, 122 1.02 [0.66, 1.51 2.13 [1.41; 3.22 7% 0dds Ratio HI, Random, 95 2.23 [1.15, 4.3] 2.13 [1.41; 3.22 7%	90] 51] 51] 63] 0.1 0.5 1 2 0.1 0.5 1 2
8 83 1 54 3063 3063 43 243 3064 3064 45 2073 45 2073 45 2073 45 2073 45 2075 5 2061 15 2061 15 206 15 206 15 206 15 206 15 206 15 207 10 207 10 20 10 10 10 10 10 10 10 10 10 1	15.3%, 5.6%, 15.5%, 15.5%, 15.5%, 15.5%, 15.5%, 15.5%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2%, 15.2\%, 15.	2 45 [114; 54] 1.74 [0.22; 13] 0.56 [0.26; 11] 2.64 [1.50; 4.3] 0.65 [0.26] 1.74 [0.22; 13] 0.65 [0.26] 1.74 [0.26] 1.75 [14] 0.75 [14] 1.75 [14] 1.75 [14] 1.75 [14] 0.75 [14	51] 449] 1,63] 0,1 0,5 1 2 0,1 0,5 1 2 0,1 0,5 1 2 0,2 0,5 1 2 0,3 0 0,4 0 0,1 0,5 1 2 0,2 0,5 1 2 0,2 0,5 1 2 0,2 0,5 1 2 0,3 0 0,4 0 0,1 0,5 1 2 0,2 0,5 1 2 0,2 0,5 1 2 0,2 0,5 1 2 0,4 0 0,5 0 0
31         243           3063         3063           int Bath         int Bath           int Bath         9           is Total W         9           9         163           9         163           9         814           17         222           103         33688           17         222           103         9           17         222           103         9           17         222           103         9           17         222           103         9           12         9           12         104           12         751           27         704           751         27           12         704           14         1770	15.5% 100.0% (); l <sup>2</sup> = 789 12.8% 13.8%	174 (0.22, 13. 0.56 (0.26, 1): 2.64 (1.50; 4) 5 0dds Ratio IH, Random, 95 3.95 [1.84, 8:46 3.22 [2.18, 4:76 3.03 [1.44, 6:53 1.02 [0.69, 1:51 2.13 [1.41; 3.22 7% 0dds Ratio IH, Random, 95 2.23 [1.15, 4.3] 2.13 [1.41; 3.22 7%	4.6) 1.7] 6.63] 0.1 0.5 1 2 0.1 0.5 1 2
3063         3063           of 6 (P < 0.01	100.0% ): r <sup>1</sup> = 763 Yeight M 12.8% 18.9% 12.7% 18.9% 12.7% 18.9% 12.7% 18.8% 00.0% 11. r <sup>2</sup> = 77 2.7% 5.6% 5.3% 5.3% 6.3% 5.8% 6.3%	2.54 [1.50; 4.1 6 Odds Ratio H, Random, 957 3.95 [1.84; 8.43 3.22 [2.16; 4.75 3.03 [1.4, 75 3.03 [1.4, 75 3.03 [1.4, 75 3.03 [1.4, 75 3.03 [1.4, 75 1.02 [0.69; 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, 95 2.23 [1.15; 4.3] 2.18 [1.70; 27 1.72 [1.37; 21] 1.66 [1.08; 1.25] 2.13 [1.64; 1.84 1.37 [0.81; 2.5] 1.38 [1.04; 1.85] 1.37 [0.81; 2.5] 1.38 [1.04; 1.85] 1.37 [0.81; 2.5] 1.37 [0.81; 2.5] 1	63] 0.1 0.5 1 2 % CI MH, Random, 95 9] 9] 9] 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.3 0dds Ratio 65% CI MH, Random, 95 10] 10] 10] 10] 10] 10] 10] 10]
Female         Female           ts         704           75         266           76         773           77         773           78         774           774         775           775         784           774         775           775         775           78         774           775         775	Veight M 12.8% 18.9% 17.9% 18.8% 00.0% 01): i <sup>2</sup> = 77 Weight 3. 2.7% 5.6% 5.6% 5.3% 5.3% 5.3% 6.3%	Odds Ratio H, Random, <b>95</b> 3.95 [1.84; 8.46 3.22 [216; 4.75 3.03 [1.46; 75] 1.62 [160; 1.51 2.13 [1.41; 3.22 75 Odds Ratio HH, Random, <b>99</b> 2.23 [1.15; 4.3] 2.18 [1.70; 2.7] 1.72 [1.37; 2.41 1.64 [1.70; 2.7] 1.64 [1.25; 2.11 1.64 [1.25; 2.11] 1.64 [1.25] 1.6	0.1 0.5 1 2 % CI MH, Random, 99 91 51 92 10 0.2 0.5 1 2 0.2 0.5 1 2 0.5 0 0 0.5 0 0 0
Ht Bath         s Total W           is 7 57al W         is 7 57al W           i2 1783 1         is 9 163 1           i2 1783 1         is 2 15 266 1           i5 266 1         is 3568 1(1)           i5 266 1         is 5 26 1           i5 266 1         is 7 561 1           i5 942 1         is 378 33 468 19 1977           i5 378 33 468 19 1977         is 7 3499 1972           i5 373 4999 22 70         is 7 3499 177           i5 11 1770         is 11 1770	Veight M 12.8% 18.9% 17.9% 18.9% 17.9% 18.8% 00.0% 11); i <sup>2</sup> = 77 Weight 1 2.7% 5.8% 5.8% 5.8% 5.3% 5.3% 6.3%	Odds Ratio H, Random, 957 3.95 [1.84, 8.4 3.22 [2.16, 4.75 3.03 [1.40, 6.53 1.02 [0.69; 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, 95 2.23 [1.15, 4.3] 2.18 [1.70; 2.7 1.72 [1.73; 2.11 1.64 [1.25; 2.11 1.65 [0.88]; 3.1 1.65 [0.81; 2.5] 1.65 [1.25] [1.64] [1.64] [1.65]	Odds Ratio           % Cl         MH, Random, 95           9]         31           01         21           02         0.5         1           7% Cl         MH, Random, 95           6% Cl         MH, Random, 95           7% Cl         MH, Random, 95           10         0.2         0.5           7% Cl         MH, Random, 95           10         1         1           11         0.2         0.5         1           12         0.2         0.5         1         2           13         0.5         1         2         1           14         1         1         1         1
is Total W           is Total V           is 5           is 6           is 7           is 8           is 8           is 9           is 10           is 10           is 26           is 266           is 266           is 266           is 267           is 3068           is 267           is 3068           is 3068           is 267           is 30           is 31	U U U U U U U U U U U U U U U U U U U	Ht, Random, 957 3.95 [1.84; 8.46 3.22 [2.16; 4.75 3.03 [1.40; 6.53 1.79 [1.34; 2.95 1.10 [0.69; 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, 99 2.23 [1.15; 4.3] 2.18 [1.70; 2.7 1.72 [1.77; 2.11 1.66 [1.25]; 2.11 1.67 [1.25]; 2.11 1.77 [1.25]; 2.11]; 3.11 1.77 [1.25]; 3.11];	% CI         MH, Random, 95           9         51           51         31           01         02           02         0.5           03         0           04         0.2           05         MH, Random, 95           06         0.2           07         0.2           08         0.4           09         0.4
is Total W           is Total V           is 5           is 6           is 7           is 8           is 8           is 9           is 10           is 10           is 26           is 266           is 266           is 266           is 267           is 3068           is 267           is 3068           is 3068           is 267           is 30           is 31	U U U U U U U U U U U U U U U U U U U	Ht, Random, 957 3.95 [1.84; 8.46 3.22 [2.16; 4.75 3.03 [1.40; 6.53 1.79 [1.34; 2.95 1.10 [0.69; 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, 99 2.23 [1.15; 4.3] 2.18 [1.70; 2.7 1.72 [1.77; 2.11 1.66 [1.25]; 2.11 1.67 [1.25]; 2.11 1.77 [1.25]; 2.11]; 3.11 1.77 [1.25]; 3.11];	% CI         MH, Random, 95           9         51           51         31           01         02           02         0.5           03         0           04         0.2           05         MH, Random, 95           06         0.2           07         0.2           08         0.4           09         0.4
is Total W           is Total V           is 5           is 6           is 7           is 8           is 8           is 9           is 10           is 10           is 26           is 266           is 266           is 266           is 267           is 3068           is 267           is 3068           is 3068           is 267           is 30           is 31	U U U U U U U U U U U U U U U U U U U	Ht, Random, 957 3.95 [1.84; 8.46 3.22 [2.16; 4.75 3.03 [1.40; 6.53 1.79 [1.34; 2.95 1.10 [0.69; 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, 99 2.23 [1.15; 4.3] 2.18 [1.70; 2.7 1.72 [1.77; 2.11 1.66 [1.25]; 2.11 1.67 [1.25]; 2.11 1.77 [1.25]; 2.11]; 3.11 1.77 [1.25]; 3.11];	% CI         MH, Random, 95           9         51           51         31           01         02           02         0.5           03         0           04         0.2           05         MH, Random, 95           06         0.2           07         0.2           08         0.4           09         0.4
2 1783 1 9 163 1 5 9 164 1 5 92 1 3568 1(1 7 222 15 942 1 7 222 15 942 1 15 942 1 7 222 15 942 1 15 942 1 15 378 3 91 797 74 761 2 751 3 78 499 9 75 14 1770	18.9% 12.7% 18.9% 18.9% 18.8% 00.0% 01); i <sup>2</sup> = 77 5.6% 5.4% 5.4% 5.4% 5.3% 5.3% 5.3% 5.3% 6.3%	212 [216, 475 303 [140; 653 1,77 [134; 200; 657 1,02 [066; 1,51 2,13 [141; 3,22 2,13 [141; 3,22 7% Odds Ratio MH, Random, 95 2,23 [1,15; 4,3] 2,18 [170; 27 1,72 [137; 24] 1,66 [108; 1,25] 1,15 [4,16] [15; 4,3] 2,18 [170; 27] 1,72 [137; 24] 1,66 [108; 1,25] 1,37 [106; 1,26] 1,37	51 30 31 31 32 32 32 32 32 32 32 32 32 32
9 9 163 1 9 814 3 5 206 1 3568 10 5 206 1 5 206 1 5 206 1 5 206 1 5 206 1 5 206 1 7 222 5 7 10 7 5 10 7 5 10 7 5 10 7 10 7 2 10 7 10 7 10 7 10 7 10 7 10 7 10 7 10 7	12.7% 18.9% 17.9% 18.8% 00.0% 11); i <sup>2</sup> = 77 2.7% 5.6% 5.4% 5.4% 5.4% 5.4% 5.3% 5.3% 5.3% 5.3% 6.3%	3 03 [140; 653 1.97 [134; 290 1.61 [103] 252 1.02 [0.68; 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, 95 2.23 [1.15, 4.3 2.18 [1.70, 27 1.72 [1.37, 21] 1.64 [1.25, 21] 1.64 [1.25, 21] 1.65 [0.88] 31 1.65 [0.86] 32 1.65 [0.86] 2.5 1.65 [0.86] 2.5 [0.86]	3) 3) 3) 3) 3) 4) 4) 5) 5) 5) 6) 6) 6) 6) 6) 6) 6) 7) 6) 6) 7) 7) 7) 7) 7) 7) 7) 7) 7) 7
9         814         1           5         92         1           3566         11         3566         1           3567         10         2         1           7         22         103         33         468           90         751         378         33         468           90         757         2762         773         4969           22         70         74         4969         74           41         1770         141         1770         141	18.9% 17.9% 18.8% 00.0% 01); i <sup>2</sup> = 77 2.7% 5.6% 5.6% 5.4% 5.1% 5.1% 5.1% 5.3% 5.5% 6.3%	197 [134; 296 1.61 [103; 252 1.61 [103; 252 1.61 [102] [068; 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, \$9 2.23 [1.15; 4.3] 2.18 [170; 27 1.72 [137; 21] 1.66 [1.28; 2.11 1.64 [1.25; 21] 1.64 [1.64; 18] 1.63 [1.64; 18] 1.67 [	0] 2] 1] 2] 02 0.5 1 2 0 0 0dds Ratio 5% CI MH, Random, 957 10] 10] 10] 10] 10] 10] 10] 10] 10] 10]
5         92         1           3568 10         3568 10           =5 (P < 0.0	17.9% 18.8% 00.0% 01.1; i <sup>2</sup> = 77 9.1; i <sup>3</sup> = 77 9.	161 [1 03; 252 1.02 [069; 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, 95 2.23 [1.15; 4.3] 2.18 [1.70; 27 1.72 [1.37; 21] 1.66 [1.28]; 21 1.66 [1.28]; 21 1.66 [1.28]; 21 1.37 [06]; 2.5 1.37 [06]; 2.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1	2] 1] 2] 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.4 MH, Random, 95 10] 10] 10] 10] 10] 10] 10] 10]
Female           sts         266         1           sts         Total         1           rs         7         222         103           rd         721         240         751           rd         72         1603         737           rd         468         90         757           rd         469         751         474           rd         752         73         4989           rd         754         141         1770	18.8% 00.0% 01); i <sup>2</sup> = 77 91); i <sup>2</sup> = 77 91); i <sup>2</sup> = 77 9, 19 5, 1% 5, 1% 5, 1% 5, 1% 5, 1% 5, 1% 5, 1% 5, 1% 5, 1% 6, 3% 6, 8%	1.02 [0.69: 1.51 2.13 [1.41; 3.22 7% Odds Ratio MH, Random, \$9 2.23 [1.15; 4.3] 2.18 [1.70; 2.71 1.66 [0.88; 3.1; 1.64 [1.25; 2.11 1.64 [1.25; 2.11 1.37 [0.61; 2.5] 1.37 [0.61; 2.5] 1.37 [0.61; 2.5]	1] 2] 0.2 0.5 1 2 0.6 0dds Ratio 5% CI MH, Random, 957 10] 10] 10] 10] 10] 10] 10] 10]
3568 10           = 5 (P < 0.0	00.0% Weight N 2.7% 5.6% 5.7% 5.8% 5.3% 5.8% 5.3% 5.8% 5	2.13 [1.41; 3.22 Odds Ratio MH, Random, 99 2.23 [1.15; 4.3] 2.18 [1.70; 2.7] 1.72 [1.37; 2.1] 1.64 [0.88; 3.1] 1.64 [1.65; 2.1] 1.38 [1.04; 1.8] 1.37 [0.81; 2.3] 1.37 [0.81; 2.3]	2) 0.2 0.5 1 2 0.2 0.5 1 2 0.2 0.5 1 2 0.4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Female ts Total 1 17 222 15 942 72 1103 15 378 33 468 91 797 04 751 27 664 751 4969 22 70 67 514 41 1770	Weight M 2.7% 5.6% 5.4% 5.4% 5.4% 5.3% 6.3% 6.6%	Odds Ratio MH, Random, 99 223 [1.15, 4.3] 2.18 [170, 27, 17] 1.72 [1.37, 2.11 1.66 [1088, 3.1] 1.64 [125, 22] 1.37 [104; 1.8] 1.37 [104; 1.8] 1.37 [104; 1.8]	Odds Ratio Odds Ratio S% CI MH, Random, 957 101 101 101 101 101 101 101 10
Female           tts         Total           17         222           15         942           72         1103           15         378           33         468           91         797           04         751           27         664           74         2762           50         737           34989         22           70         67           614         1770	Weight M 2.7% 5.6% 5.7% 2.8% 5.4% 5.3% 5.3% 6.3% 6.6%	Odds Ratio MH, Random, \$9 2.23 (1.15, 4.3) 2.18 (1.70; 2.77 1.72 (1.37; 2.14 1.66 (1.26; 2.17) 1.64 (1.25; 2.17) 1.35 (1.04; 1.84 1.37 (0.81; 2.34) 1.37 (0.81; 2.34)	Odds Ratio MH, Random, 957 10] 10] 10] 10] 10] 10] 10] 10] 10] 10]
tts Total 1 17 222 15 942 72 1103 15 378 33 468 91 797 04 751 27 664 74 2762 50 737 73 4969 22 70 67 514 14 1770	2.7% 5.6% 5.7% 2.8% 5.4% 5.3% 5.3% 6.3% 5.6% 6.6%	MH, Random, 99 2.23 (1.15; 4.3) 2.18 (1.70; 2.7) 1.72 (1.37; 2.1) 1.66 (0.88; 3.1) 1.64 (1.25; 2.1) 1.45 (1.07; 1.9) 1.38 (1.04; 1.8; 1.37 (0.81; 2.3) 1.28 (1.10; 1.49)	Odds Ratio MH, Random, 957 10] 10] 10] 10] 10] 10] 10] 10] 10] 10]
15         942           72         1103           15         378           33         468           91         797           04         751           27         664           74         2762           50         737           73         4969           22         70           67         514           14         1770	5.6% 5.7% 2.8% 5.4% 5.3% 3.4% 6.3% 5.6% 6.6%	2.18 [1.70; 2.7/ 1.72 [1.37; 2.10 1.66 [0.88; 3.1] 1.64 [1.25; 2.1] 1.45 [1.07; 1.9] 1.38 [1.04; 1.8] 1.37 [0.81; 2.3 1.28 [1.10; 1.4]	18]
72 1103 15 378 33 468 91 797 04 751 27 664 74 2762 50 737 73 4989 22 70 67 514 14 1770	5.7% 2.8% 5.4% 5.1% 5.3% 6.3% 5.6% 6.6%	1.72 [1.37; 2.10 1.66 [0.88; 3.1] 1.64 [1.25; 2.1] 1.45 [1.07; 1.9] 1.38 [1.04; 1.80 1.37 [0.81; 2.3 1.28 [1.10; 1.49	16] 12] 15] 15] 13] 14] 19]
15         378           33         468           91         797           04         751           27         664           74         2762           50         737           73         4989           22         70           67         514           14         1770	2.8% 5.4% 5.3% 3.4% 6.3% 5.6% 6.6%	1.66 [0.88; 3.1] 1.64 [1.25; 2.1] 1.45 [1.07; 1.9] 1.38 [1.04; 1.8] 1.37 [0.81; 2.3] 1.28 [1.10; 1.4]	12] 15] 17] 13] 14]
91         797           04         751           27         664           74         2762           50         737           73         4989           22         70           67         514           14         1770	5.1% 5.3% 3.4% 6.3% 5.6% 6.6%	1.64 [1.25; 2.15 1.45 [1.07; 1.97 1.38 [1.04; 1.85 1.37 [0.81; 2.3- 1.28 [1.10; 1.45	15]
04 751 27 664 74 2762 50 737 73 4989 22 70 67 514 14 1770	5.3% 3.4% 6.3% 5.6% 6.6%	1.38 [1.04; 1.8 1.37 [0.81; 2.3 1.28 [1.10; 1.4	13] 14]
27 664 74 2762 50 737 73 4989 22 70 67 514 14 1770	3.4% 6.3% 5.6% 6.6%	1.37 (0.81; 2.3 1.28 (1.10; 1.4)	14]
74 2762 50 737 73 4989 22 70 67 514 14 1770	6.3% 5.6% 6.6%	1.28 [1.10; 1.45	19]
50         737           73         4989           22         70           67         514           14         1770	5.6% 6.6%		
22 70 67 514 14 1770			
67 514 14 1770	2.7%	1.17 [1.05; 1.3	
14 1770		1.16 [0.60; 2.2	
	5.4% 6.2%	1.13 [0.87; 1.4 1.11 [0.93; 1.3	
45 415	4.1%	1.07 [0.69; 1.6	
70 299	4.5%	1.05 (0.72; 1.5	M
59 397	4.4%	0.95 [0.65; 1.4	
61 5491	6.6%	0.87 [0.80; 0.9	
52 1087 92 1575	4.2%	0.81 [0.53; 1.24	
8 57	5.5%	0.62 [0.48, 0.8	
11 234	1.2%	0.32 [0.10; 1.0	
25722	100.0%	1.19 [1.04; 1.3]	17]
21 (P < 0.01			
			0.1 0.5 1 2
		Odds Ratio	Odds Ratio
		H, Random, 95%	CI MH, Random, 95%
		2.76 [1.67; 4.57]	
		0.83 [0.54; 1.25]	
			. –
-0(r = 0)	.urj, i = 8		0.5 1 2
	0 894 2 8 205 2 1 1772 2 1 202 2 3073 10	5 Total Weight Mi 0 894 23.0% 3 205 24.0% 1 772 28.2% 1 202 24.9% 3073 100.0%	Total Weight MH, Random, 95%           0         894         23.0%         2.76 [1.67, 4.57           2         0.5         24.0%         2.63 [1.67, 4.15           1         1772         28.2%         1.69 [1.32, 2.16           2         0.2         24.9%         0.83 [0.54, 1.25

Contact No Contact Odds Ratio Events Total Events Total Weight MH, Random, 95% Cl

184 490 8 947 14.1% 70.58 [34.37; 144.93]

(ETH) Yirgu et al

Our study provides a contemporary estimate of the prevalence and risk factors associated with scabies at a global level. This meta-analysis found a global prevalence of 11.9% (95% CI 9.60%-14.7%) with substantial heterogeneity ( $I^2 = 100\%$ ;  $\tau^2 = 1.04$ ) As  $I^2$  is highly dependent on the precision of the studies (90,91), it tends towards 100% as the number of studies included becomes large, since the sampling error of the pooled estimate is reduced. We found substantial heterogeneity in between-study prevalence, some of which was explained by subgroup differences. The subgroup analysis found a higher prevalence of scabies in studies conducted in the Western Pacific region. Surprisingly, country level socio-economic factors (like GDP, HDI and Gini index) were independent of scabies prevalence. Behavioral factors including infrequent bathing, lack of soap use, contact with persons with history of itch and clothes or bed-sharing were associated with higher disease risk.

A strength of this study was the comprehensive search strategy and use of PRISMA guidelines to review and include studies was likely to minimise selection bias. With 70 studies, this is the most comprehensive meta-analysis estimating the prevalence of scabies. In addition, this study considers a wide range of countries and populations with respect to geographic regions, ages, diagnostic techniques, and socioeconomic status.

This study has some limitations. First, most of the studies included were from the Western Pacific, African and South-East Asian regions, whereas only seven were from Europe and none from the Americas. This may have led to an underrepresentation and underestimation of scabies prevalence in the latter areas. Second, studies are more likely to be conducted in areas with high prevalence of scabies. Thus, pooled estimate using prevalence studies most likely overestimated the true global prevalence. Third, several risk factors such as literacy of parents and caregivers, employment status of parents, household overcrowding, and presence of sanitation facilities in the household, were not considered by the studies included in this analysis. Fourth, since different studies have considered different sets of risk factors with differing definitions, the pooled odds ratios presented in this paper is likely to be affected by measurement error. Fifth, the study has considered socio-economic factors at the country level as a proxy for every study. Since each study is based on a select population having their own unique economic characteristics, considering a macro level economic indicator may distort its association with scabies prevalence. Finally, since this study has pooled results from studies using different diagnostic techniques, this contributes to measurement error in individual studies, which likely leads to between study heterogeneity. Even though some definitions are consistent between studies, most studies rely on clinical assessment that is unavoidably subjective.

Romani et al, in 2015 (92), conducted a meta-analysis of 48 studies and concluded that scabies prevalence was highest in Latin America and Pacific regions. The findings of our study are consistent since this study also noted a significantly higher burden of scabies in the Pacific region in comparison to the others. Another recent meta-analysis (93) reported a very wide range of scabies prevalence from 0.18% to 79.6% as did the study by Romani which had a range from 0.2% to 71.4%. The pooled prevalence in our study is similar with a pooled 95% confidence interval ranging between 0.4% and 71%. We believe the main reason for such wide variation is the use of several diagnostic techniques like IACS, IMCI, and traditional methods. Thus, standardising diagnostic criteria for scabies through using the IACS method, for example, has already been recommended (94). Since these diagnostic techniques such as the quantitative polymerase chain reaction (qPCR) (95). Although these meta-analyses have discussed the important issues of global prevalence, diagnostic inconsistency and need of MDA, they have, however, not considered pooling risk factors. Our study is the first to consider this evidence.

This study has considered multiple socioeconomic and behavioural factors that are likely to affect scabies prevalence. Summary measures of a country's economic status like GDP, HDI and Gini index were not associated with scabies prevalence. This contrasts with several other ecological studies (96,97) as well as cross-sectional studies (98,99) that report evidence of higher burden of scabies in countries with lower GDP and low family income. One community-based study (98) has linked poor

economic conditions to behavioural factors like infrequent bathing, soap use or washing clothes, in turn increasing the chances of scabies incidence or reinfection. The contrast in results of this study to those reported previously is likely due to the use of national GDP as a proxy for each community. There is an ecological bias in our study as summary measures at a country level don't necessarily apply to specific populations studied. Further, since factors like income influence behaviour rather than directly influencing disease status, the role of income may be as a mediator rather than an independent causal factor.

The behavioural factors: history of contact with a person with itch; and sharing beds and clothes are consistent with past findings and are biologically plausible. Sharing clothes poses a very high risk of developing scabies (38) (99,100). Similarly, sharing towels and bed linen was strongly associated with a high prevalence of scabies cases in a study based in semi-urban India (101). Bed-sharing was strongly associated with the risk of scabies which is concordant with the results of a similar study conducted in Ethiopia (102). However, their findings of an association between family size and scabies status contrasts with those from this study. Since family size is a crude measure of crowding, it might be better to consider a measure such as household crowding index to determine the nature of this association in future studies.

In this study a strong association was observed between the presence of pets and scabies. Few studies to date have considered the risk of scabies due to pets because of the presumed biological implausibility. The pooled results from three studies provide evidence of this association. While zoonotic scabies (ZS) is often considered incapable of thriving on human skin leading to it being perceived as a self-limited disease (103), increasing evidence indicates that symptoms from ZS may persist for several weeks until an effective treatment is administered (104). Recent instances of transmission of the scabies parasite from animals, especially dogs, to humans have been reported (105,106). Also, pets may act as a 'fomite' which facilitates the transmission of human-to-human scabies.

The role that hygiene plays in scabies infestation is controversial and some authors dismiss these factors as not significant (107). However, several studies argue otherwise (38,98). Our study has found strong evidence of lower scabies prevalence in populations who have frequently bathe with soap. Untreated and scarce water supply leading to poor personal hygiene has been suspected to contribute to scabies burden in LMICs (38). While it is unclear if soap use directly has any preventive effect against scabies infestation, the authors of one study have stated that soap use can ameliorate the symptoms by reducing the number of active scabies lesions (108). It has also been hypothesized that regular bathing and soap use acts as a protective factor in resource poor settings (99).

Our study has provided strong evidence of the high global burden of scabies and of a number of behavioural risk factors. The evidence we have summarised indicates that specific risk factors are strongly associated with transmission. Specific measures to reduce scabies prevalence, such as mass drug administration (MDA), are now recommended by the World Health Organization for populations with a prevalence of scabies of more than 10% (96). Our study also suggests that targeted interventions that reduce risk factors such as sharing of clothes and beds and improving access to treated water and soap are also likely to reduce scabies burden.

## Conclusion

The prevalence of scabies worldwide remains high. In addition to targeted MDA, our study finds several consistent risk factors which may be included in health promotion interventions to reduce scabies prevalence and its sequelae in the long term.

## References

- 1. Karimkhani C, Colombara DV, Drucker AM, Norton SA, Hay R, Engelman D, et al. The global burden of scabies: a cross-sectional analysis from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017 Dec;17(12):1247–54.
- Engelman D, Kiang K, Chosidow O, McCarthy J, Fuller C, Lammie P, et al. Toward the Global Control of Human Scabies: Introducing the International Alliance for the Control of Scabies. Vinetz JM, editor. PLoS Negl Trop Dis. 2013 Aug 8;7(8):e2167.
- 3. Lynar S, Currie BJ, Baird R. Scabies and mortality. Lancet Infect Dis. 2017 Dec;17(12):1234.
- 4. Engelman D, Cantey PT, Marks M, Solomon AW, Chang AY, Chosidow O, et al. The public health control of scabies: priorities for research and action. The Lancet. 2019 Jul;394(10192):81–92.
- 5. Chosidow O, Fuller LC. Scratching the itch: is scabies a truly neglected disease? Lancet Infect Dis. 2017 Dec;17(12):1220–1.
- 6. Cavoli GI, Bono L, Tortorici C, Li Cavoli T, Rotolo U. Membranous glomerulonephritis overlapping with scabies. Indian J Nephrol. 2016;26(4):312.
- 7. Thornley S, Marshall R, Jarrett P, Sundborn G, Reynolds E, Schofield G. Scabies is strongly associated with acute rheumatic fever in a cohort study of Auckland children. J Paediatr Child Health. 2018 Jun;54(6):625–32.
- Worth C, Heukelbach J, Fengler G, Walter B, Liesenfeld O, Feldmeier H. Impaired quality of life in adults and children with scabies from an impoverished community in Brazil. Int J Dermatol. 2012 Mar;51(3):275–82.
- Jin-gang A, Sheng-xiang X, Sheng-bin X, Jun-min W, Song-mei G, Ying-ying D, et al. Quality of life of patients with scabies. J Eur Acad Dermatol Venereol. 2010 Oct;24(10):1187–91.
- 10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;n71.
- 11. Behera P, Munshi H, Kalkonde Y, Deshmukh M, Bang A. Control of scabies in a tribal community using mass screening and treatment with oral ivermectin -A cluster randomized controlled trial in Gadchiroli, India. Pathmeswaran A, editor. PLoS Negl Trop Dis. 2021 Apr 16;15(4):e0009330.
- 12. Galván-Casas C, Mitjá O, Esteban S, Kafulafula J, Phiri T, Navarro-Fernández Í, et al. A facility and community-based assessment of scabies in rural Malawi. Chandler DJ, editor. PLoS Negl Trop Dis. 2021 Jun 1;15(6):e0009386.
- 13. Coscione S, Esau T, Kekeubata E, Diau J, Asugeni R, MacLaren D, et al. Impact of ivermectin administered for scabies treatment on the prevalence of head lice in Atoifi, Solomon Islands. Murdoch M, editor. PLoS Negl Trop Dis. 2018 Sep 25;12(9):e0006825.
- Haar K, Romani L, Filimone R, Kishore K, Tuicakau M, Koroivueta J, et al. Scabies community prevalence and mass drug administration in two F ijian villages. Int J Dermatol. 2014 Jun;53(6):739–45.

- 15. Kearns TM, Speare R, Cheng AC, McCarthy J, Carapetis JR, Holt DC, et al. Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community. Vinetz JM, editor. PLoS Negl Trop Dis. 2015 Oct 30;9(10):e0004151.
- 16. Marks M, Romani L, Sokana O, Neko L, Harrington R, Nasi T, et al. Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin. Clin Infect Dis. 2020 Apr 10;70(8):1591–5.
- 17. Martin D, Wiegand R, Goodhew B, Lammie P, Mkocha H, Kasubi M. Impact of Ivermectin Mass Drug Administration for Lymphatic Filariasis on Scabies in Eight Villages in Kongwa District, Tanzania. Am J Trop Med Hyg. 2018 Oct 3;99(4):937–9.
- Marks M, Toloka H, Baker C, Kositz C, Asugeni J, Puiahi E, et al. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. Clin Infect Dis. 2019 Mar 5;68(6):927–33.
- 19. GDP (current US\$) | Data [Internet]. [cited 2024 Aug 8]. Available from: https://data.worldbank.org/indicator/NY.GDP.MKTP.CD
- 20. World Bank Open Data [Internet]. [cited 2024 Aug 8]. World Bank Open Data. Available from: https://data.worldbank.org
- 21. Nations U. Human Development Index [Internet]. Human Development Reports. United Nations; [cited 2024 Aug 8]. Available from: https://hdr.undp.org/datacenter/human-development-index
- 22. R: The R Project for Statistical Computing [Internet]. [cited 2024 Aug 8]. Available from: https://www.r-project.org/
- 23. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539–58.
- 24. Sutton AJ, editor. Methods for meta-analysis in medical research. Repr. Chichester Weinheim: Wiley; 2002. 317 p. (Wiley series in probability and statistics).
- 25. Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002 Jun 15;21(11):1503–11.
- Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006 Oct 30;25(20):3443–57.
- 27. Peters JL. Comparison of Two Methods to Detect Publication Bias in Meta-analysis. JAMA. 2006 Feb 8;295(6):676.
- 28. Harbord RM, Harris RJ, Sterne JAC. Updated Tests for Small-study Effects in Metaanalyses. Stata J Promot Commun Stat Stata. 2009 Aug;9(2):197–210.
- 29. Duval S, Tweedie R. A Nonparametric "Trim and Fill" Method of Accounting for Publication Bias in Meta-Analysis. J Am Stat Assoc. 2000 Mar;95(449):89–98.
- Amare HH, Lindtjorn B. Risk factors for scabies, tungiasis, and tinea infections among schoolchildren in southern Ethiopia: A cross-sectional Bayesian multilevel model. Ekpo UF, editor. PLoS Negl Trop Dis. 2021 Oct 6;15(10):e0009816.

- Bogino EA, Woldegeorgis BZ, Wondewosen L, Dessu BK, Obsa MS, Hanfore LK, et al. Scabies prevalence and its associated factors among prisoners in southern Ethiopia: An institution-based analytical cross-sectional study. Beebe N, editor. PLoS Negl Trop Dis. 2023 Dec 22;17(12):e0011826.
- Yirgu R, Middleton J, Fekadu A, Cassell JA, Tesfaye A, Jones CI, et al. Scabies in the Amhara region of northern Ethiopia: a cross-sectional study of prevalence, determinants, clinical presentation and community knowledge. BMJ Open. 2023 Oct;13(10):e075038.
- 33. Ararsa G, Merdassa E, Shibiru T, Etafa W. Prevalence of scabies and associated factors among children aged 5–14 years in Meta Robi District, Ethiopia. Egata G, editor. PLOS ONE. 2023 Jan 3;18(1):e0277912.
- 34. Dagne H, Dessie A, Destaw B, Yallew WW, Gizaw Z. Prevalence and associated factors of scabies among schoolchildren in Dabat district, northwest Ethiopia, 2018. Environ Health Prev Med. 2019 Dec;24(1):67.
- 35. Enbiale W, Ayalew A. Investigation of a Scabies Outbreak in Drought-Affected Areas in Ethiopia. Trop Med Infect Dis. 2018 Oct 29;3(4):114.
- 36. Enbiale W, Baynie TB, Ayalew A, Gebrehiwot T, Getanew T, Ayal A, et al. "Stopping the itch": mass drug administration for scabies outbreak control covered for over nine million people in Ethiopia. J Infect Dev Ctries. 2020 Jun 30;14(06.1):28S-35S.
- Haile T, Sisay T, Jemere T. Scabies and its associated factors among under 15 year's children in Wadila district, Northern Ethiopia, 2019. Pan Afr Med J [Internet]. 2020 [cited 2024 Aug 8];37. Available from: https://www.panafrican-medjournal.com/content/article/37/224/full
- 38. Melese F, Malede A, Sisay T, Geremew A, Gebrehiwot M, Woretaw L, et al. Cloth sharing with a scabies case considerably explains human scabies among children in a low socioeconomic rural community of Ethiopia. Trop Med Health. 2023 Sep 15;51(1):52.
- Misganaw B, Nigatu SG, Gebrie GN, Kibret AA. Prevalence and determinants of scabies among school-age children in Central Armachiho district, Northwest, Ethiopia. Umer MF, editor. PLOS ONE. 2022 Jun 14;17(6):e0269918.
- 40. Sara J, Haji Y, Gebretsadik A. Scabies Outbreak Investigation and Risk Factors in East Badewacho District, Southern Ethiopia: Unmatched Case Control Study. Dermatol Res Pract. 2018 Jun 26;2018:1–10.
- 41. Walker SL, Lebas E, De Sario V, Deyasso Z, Doni SN, Marks M, et al. The prevalence and association with health-related quality of life of tungiasis and scabies in schoolchildren in southern Ethiopia. Picardeau M, editor. PLoS Negl Trop Dis. 2017 Aug 3;11(8):e0005808.
- 42. Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, et al. Community control strategies for scabies: A cluster randomised noninferiority trial. Von Seidlein L, editor. PLOS Med. 2021 Nov 10;18(11):e1003849.
- 43. Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, et al. The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial. Specht S, editor. PLoS Negl Trop Dis. 2020 Mar 16;14(3):e0008106.

- 44. Romani L, Koroivueta J, Steer AC, Kama M, Kaldor JM, Wand H, et al. Scabies and Impetigo Prevalence and Risk Factors in Fiji: A National Survey. McCarthy JS, editor. PLoS Negl Trop Dis. 2015 Mar 4;9(3):e0003452.
- 45. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, et al. The Epidemiology of Scabies and Impetigo in Relation to Demographic and Residential Characteristics: Baseline Findings from the Skin Health Intervention Fiji Trial. Am J Trop Med Hyg. 2017 Sep 7;97(3):845–50.
- 46. Steer AC, Jenney AWJ, Kado J, Batzloff MR, La Vincente S, Waqatakirewa L, et al. High Burden of Impetigo and Scabies in a Tropical Country. Franco-Paredes C, editor. PLoS Negl Trop Dis. 2009 Jun 23;3(6):e467.
- 47. Tsoi SK, Lake SJ, Thean LJ, Matthews A, Sokana O, Kama M, et al. Estimation of scabies prevalence using simplified criteria and mapping procedures in three Pacific and southeast Asian countries. BMC Public Health. 2021 Dec;21(1):2060.
- 48. Lake SJ, Engelman D, Sokana O, Nasi T, Boara D, Grobler AC, et al. Defining the need for public health control of scabies in Solomon Islands. Hay R, editor. PLoS Negl Trop Dis. 2021 Feb 22;15(2):e0009142.
- 49. Mason DS, Marks M, Sokana O, Solomon AW, Mabey DC, Romani L, et al. The Prevalence of Scabies and Impetigo in the Solomon Islands: A Population-Based Survey. Vinetz JM, editor. PLoS Negl Trop Dis. 2016 Jun 27;10(6):e0004803.
- Osti MH, Sokana O, Phelan S, Marks M, Whitfeld MJ, Gorae C, et al. Prevalence of scabies and impetigo in the Solomon Islands: a school survey. BMC Infect Dis. 2019 Dec;19(1):803.
- 51. Korte LM, Bowen AC, Draper ADK, Davis K, Steel A, Teodora I, et al. Scabies and impetigo in Timor-Leste: A school screening study in two districts. Taylan Ozkan A, editor. PLoS Negl Trop Dis. 2018 May 31;12(5):e0006400.
- 52. Matthews A, Le B, Amaral S, Arkell P, Monteiro M, Clarke N, et al. Prevalence of scabies and impetigo in school-age children in Timor-Leste. Parasit Vectors. 2021 Dec;14(1):156.
- 53. Dos Santos MM, Amaral S, Harmen SP, Joseph HM, Fernandes JL, Counahan ML. The prevalence of common skin infections in four districts in Timor-Leste: a cross sectional survey. BMC Infect Dis. 2010 Dec;10(1):61.
- Grills N, Grills C, Spelman T, Stoove M, Hellard M, El-Hayek C, et al. Prevalence survey of dermatological conditions in mountainous north India. Int J Dermatol. 2012 May;51(5):579–87.
- 55. Burman, Abhishek Kumar, Bansal, Rahule, Sharma, Saurabh, Krishna, Arvind, Ahmad, Sartaj. An Epidemiological Study of Prevalence of Skin Diseases among Secondary School Going Children in District Meerut. Indian J Public Health Res Dev [Internet]. 2020 Jun 26 [cited 2024 Aug 8]; Available from: http://medicopublication.com/index.php/ijphrd/article/view/9741
- 56. Devidas J, Mohapatra J, Dehury P, Dehury RK. Socio-demographic and Morbidity Pattern among Under-Five Children in Rural Areas of Adilabad District of Telangana, India. J Clin Diagn Res [Internet]. 2021 [cited 2024 Aug 8]; Available from:

https://jcdr.net/article\_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=10&page=IC17&issn=0973-709x&id=15553

- 57. Vinay S, Satyamanasa Gayatri, Shrivastava, Abhijeet, Pandi, Karuppiah, Mookkappan, Sudhagar. Prevalence of Skin Disorders (SD) among school going children of semi-urban areas in Puducherry. 2021;25(4).
- 58. Amoako YA, Phillips RO, Arthur J, Abugri MA, Akowuah E, Amoako KO, et al. A scabies outbreak in the North East Region of Ghana: The necessity for prompt intervention. Ramos AN, editor. PLoS Negl Trop Dis. 2020 Dec 22;14(12):e0008902.
- 59. Maleki Birjandi M, Oroei M, Emadi SN, Peyvandi AA, Kwabena Anang A. Scabies Among High School Students in Accra, Ghana: Risk Factors and Health Literacy. Iran Red Crescent Med J [Internet]. 2019 Aug 25 [cited 2024 Aug 8];21(8). Available from: https://archive.ircmj.com/article/21/8/ircmj-21-8-92510.pdf
- 60. Kaburi BB, Ameme DK, Adu-Asumah G, Dadzie D, Tender EK, Addeh SV, et al. Outbreak of scabies among preschool children, Accra, Ghana, 2017. BMC Public Health. 2019 Dec;19(1):746.
- 61. Ciftci IH, Karaca S, Dogru O, Cetinkaya Z, Kulac M. Prevalence of pediculosis and scabies in preschool nursery children of Afyon, Turkey. Korean J Parasitol. 2006;44(1):95.
- İnanir I, Şahin MT, Gündüz K, Dinç G, Türel A, Öztürkcan S. Prevalence of Skin Conditions in Primary School Children in Turkey: Differences Based on Socioeconomic Factors. Pediatr Dermatol. 2002 Jul;19(4):307–11.
- 63. Karaca Ural Z, Çatak B, Ağaoğlu E. Prevalence of Scabies in the Covid-19 Pandemic Period and Determination of Risk Factors for Scabies: a Hospital-Based Cross-Sectional Study in Northeast Turkey. Acta Parasitol. 2022 Jun;67(2):802–8.
- 64. Tasani M, Tong SYC, Andrews RM, Holt DC, Currie BJ, Carapetis JR, et al. The Importance of Scabies Coinfection in the Treatment Considerations for Impetigo. Pediatr Infect Dis J. 2016 Apr;35(4):374–8.
- 65. Kalu EI, Wagbatsoma V, Ogbaini-Emovon E, Nwadike VU, Ojide CK. Age and sex prevalence of infectious dermatoses among primary school children in a rural South-Eastern nigerian community. Pan Afr Med J [Internet]. 2015 [cited 2024 Aug 8];20. Available from: http://www.panafrican-med-journal.com/content/article/20/182/full/
- 66. Ogunbiyi AO, Owoaje E, Ndahi A. Prevalence of Skin Disorders in School Children in Ibadan, Nigeria. Pediatr Dermatol. 2005 Jan;22(1):6–10.
- 67. Yap FBB, Elena EMT, Pubalan M. Prevalence of Scabies and Head Lice Among Students of Secondary Boarding Schools in Kuching, Sarawak, Malaysia. Pediatr Infect Dis J. 2010 Jul;29(7):682–3.
- 68. Zayyid M, Saadah S. Prevalence of scabies and head lice among children in a welfare home in Pulau Pinang, Malaysia.
- Brouqui P, Stein A, Dupont HT, Gallian P, Badiaga S, Rolain JM, et al. Ectoparasitism and Vector-Borne Diseases in 930 Homeless People From Marseilles. Medicine (Baltimore). 2005 Jan;84(1):61–8.

- 70. Rigal É, Nourrisson C, Sciauvaud J, Pascal J, Texier C, Corbin V, et al. Skin diseases in internationally adopted children. Eur J Dermatol. 2016 Jul;26(4):370–2.
- 71. Kouotou EA, Nansseu JRN, Sangare A, Moguieu Bogne L, Sieleunou I, Adegbidi H, et al. Burden of human scabies in sub-Saharan African prisons: Evidence from the west region of Cameroon. Australas J Dermatol [Internet]. 2018 Feb [cited 2024 Aug 8];59(1). Available from: https://onlinelibrary.wiley.com/doi/10.1111/ajd.12540
- 72. Kouotou EA, Nansseu JRN, Kouawa MK, Zoung-Kanyi Bissek AC. Prevalence and drivers of human scabies among children and adolescents living and studying in Cameroonian boarding schools. Parasit Vectors. 2016 Dec;9(1):400.
- 73. Hegab D, Kato A, Kabbash I, Dabish G. Scabies among primary schoolchildren in Egypt: sociomedical environmental study in Kafr El-Sheikh administrative area. Clin Cosmet Investig Dermatol. 2015 Feb;105.
- 74. Armitage EP, Senghore E, Darboe S, Barry M, Camara J, Bah S, et al. High burden and seasonal variation of paediatric scabies and pyoderma prevalence in The Gambia: A cross-sectional study. Taylan Ozkan A, editor. PLoS Negl Trop Dis. 2019 Oct 14;13(10):e0007801.
- 75. Laraqui O, Manar N, Laraqui S, Ghailan T, Deschamps F, Hammouda R, et al. Prevalence of skin diseases amongst Moroccan fishermen. Int Marit Health. 2018 Mar 28;69(1):22–7.
- 76. Sanei-Dehkordi A, Soleimani-Ahmadi M, Zare M, Jaberhashemi SA. Risk factors associated with scabies infestation among primary schoolchildren in a low socioeconomic area in southeast of Iran. BMC Pediatr. 2021 Dec;21(1):249.
- 77. Wootton CI, Bell S, Philavanh A, Phommachack K, Soukavong M, Kidoikhammouan S, et al. Assessing skin disease and associated health-related quality of life in a rural Lao community. BMC Dermatol. 2018 Dec;18(1):11.
- Collinson S, Timothy J, Zayzay SK, Kollie KK, Lebas E, Candy N, et al. The prevalence of scabies in Monrovia, Liberia: A population-based survey. Fuller C, editor. PLoS Negl Trop Dis. 2020 Dec 7;14(12):e0008943.
- 79. Thornley S, Sundborn G, Engelman D, Roskvist R, Pasay C, Marshall R, et al. Children's scabies survey indicates high prevalence and misdiagnosis in Auckland educational institutions. J Paediatr Child Health. 2023 Dec;59(12):1296–303.
- 80. Bartosik K, Kulbaka E, Buczek W, Ciura D, Raszewska-Famielec M, Tytuła A, et al. Pediculosis capitis and scabies in nurses from Eastern Poland – occupational risk and environmental determinants. Ann Agric Environ Med. 2023 Jun 26;30(2):244–51.
- Marks M, Sammut T, Cabral MG, Teixeira Da Silva E, Goncalves A, Rodrigues A, et al. The prevalence of scabies, pyoderma and other communicable dermatoses in the Bijagos Archipelago, Guinea-Bissau. Gray DJ, editor. PLoS Negl Trop Dis. 2019 Nov 18;13(11):e0007820.
- 82. Rainer LA, Molefi TL, Kololo SO, Leeme TB, Selemogo M, Molefi M. Prevalence and associated risk factors of scabies and impetigo: A cross-sectional study in Tutume district, Botswana. Deribe K, editor. PLoS Negl Trop Dis. 2024 Jun 3;18(6):e0011495.

- Saka B, Kassang P, Gnossike P, Head MG, Akakpo AS, Teclessou JN, et al. Prevalence of skin Neglected Tropical Diseases and superficial fungal infections in two peri-urban schools and one rural community setting in Togo. Converse PJ, editor. PLoS Negl Trop Dis. 2022 Dec 19;16(12):e0010697.
- 84. Taiaroa G, Matalavea B, Tafuna'i M, Lacey JA, Price DJ, Isaia L, et al. Scabies and impetigo in Samoa: A school-based clinical and molecular epidemiological study. Lancet Reg Health West Pac. 2021 Jan;6:100081.
- 85. Hasan MJ, Rafi MA, Choudhury T, Hossain MG. Prevalence and risk factors of scabies among children living in Madrasahs (Islamic religious boarding schools) of Bangladesh: a cross-sectional study. BMJ Paediatr Open. 2024 Jun;8(1):e002421.
- Gunathilaka N, Chandrasena N, Udayanga L. Prevalence of Ectoparasitic Infections and Other Dermatological Infections and Their Associated Factors among School Children in Gampaha District, Sri Lanka. Can J Infect Dis Med Microbiol. 2019 Mar 25;2019:1–10.
- 87. Hewitt KA, Nalabanda A, Cassell JA. Scabies outbreaks in residential care homes: factors associated with late recognition, burden and impact. A mixed methods study in England. Epidemiol Infect. 2015 May;143(7):1542–51.
- Callum J, McDiarmid D, Gao Y, Armstrong M, Iavro E, Steer A. Prevalence of scabies in Sanma Province, Vanuatu. Trans R Soc Trop Med Hyg. 2019 Aug 1;113(8):500–2.
- World Health Organization, United Nations Children's Fund (UNICEF). Progress on sanitation and drinking water – 2015 update and MDG assessment [Internet]. Geneva: World Health Organization; 2015 [cited 2024 Aug 9]. Available from: https://iris.who.int/handle/10665/177752
- 90. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I2 in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008 Dec;8(1):79.
- 91. Borenstein M, Higgins JPT, Hedges LV, Rothstein HR. Basics of meta-analysis: *I*<sup>2</sup> is not an absolute measure of heterogeneity. Res Synth Methods. 2017 Mar;8(1):5–18.
- 92. Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis. 2015 Aug;15(8):960–7.
- Schneider S, Wu J, Tizek L, Ziehfreund S, Zink A. Prevalence of scabies worldwide—An updated systematic literature review in 2022. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1749–57.
- 94. Engelman D, Marks M, Steer AC, Beshah A, Biswas G, Chosidow O, et al. A framework for scabies control. Taylan Ozkan A, editor. PLoS Negl Trop Dis. 2021 Sep 2;15(9):e0009661.
- 95. Chng L, Holt DC, Field M, Francis JR, Tilakaratne D, Dekkers MH, et al. Molecular diagnosis of scabies using a novel probe-based polymerase chain reaction assay targeting high-copy number repetitive sequences in the Sarcoptes scabiei genome. Bradbury RS, editor. PLoS Negl Trop Dis. 2021 Feb 24;15(2):e0009149.

- Urban K, Giesey RL, Delost M, Delost GR. An Update on the Global Burden and Socioeconomics of Scabies: A Cross-Sectional Analysis from the Global Burden of Disease Study 2017. SKIN J Cutan Med. 2020 Oct 27;4(6):534–42.
- 97. Chu S, Mehrmal S, Uppal P, Giesey RL, Delost ME, Delost GR. Burden of skin disease and associated socioeconomic status in Europe: An ecologic study from the Global Burden of Disease Study 2017. JAAD Int. 2020 Dec;1(2):95–103.
- Karim SA, Anwar KS, Khan MAH, Mollah MAH, Nahar N, Rahman HEMR, et al. Socio-demographic characteristics of children infested with scabies in densely populated communities of residential madrashas (Islamic education institutes) in Dhaka, Bangladesh. Public Health. 2007 Dec;121(12):923–34.
- 99. Ugbomoiko US, Oyedeji SA, Babamale OA, Heukelbach J. Scabies in Resource-Poor Communities in Nasarawa State, Nigeria: Epidemiology, Clinical Features and Factors Associated with Infestation. Trop Med Infect Dis. 2018 Jun 4;3(2):59.
- 100. Feldmeier H, Jackson A, Ariza L, Lins Calheiros CM, De Lima Soares V, Oliveira FA, et al. The epidemiology of scabies in an impoverished community in rural Brazil: Presence and severity of disease are associated with poor living conditions and illiteracy. J Am Acad Dermatol. 2009 Mar;60(3):436–43.
- 101. Gulati PV, Bracanza C, Singh KP, Borker V. SCABIES IN A SEMIURBAN AREA OF INDIA: AN EPIDEMIOLOGIC STUDY. Int J Dermatol. 1977 Sep;16(7):594–8.
- 102. Azene AG, Aragaw AM, Wassie GT. Prevalence and associated factors of scabies in Ethiopia: systematic review and Meta-analysis. BMC Infect Dis. 2020 Dec;20(1):380.
- Burgess I. Sarcoptes scabiei and Scabies. In: Advances in Parasitology [Internet]. Elsevier; 1994 [cited 2024 Aug 8]. p. 235–92. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0065308X08604145
- 104. Moroni B, Rossi L, Bernigaud C, Guillot J. Zoonotic Episodes of Scabies: A Global Overview. Pathogens. 2022 Feb 6;11(2):213.
- 105. Rubini S, Zaghi S, Tazzari A, Lo Chiano F, Govoni G, Cavazzini M, et al. Scabies in wildlife animals, pets and humans: a re-emerging zoonosis? Eur J Public Health. 2021 Oct 20;31(Supplement\_3):ckab165.623.
- Bandi KM. Sarcoptic Mange: A Zoonotic Ectoparasitic Skin Disease. J Clin Diagn Res [Internet]. 2013 [cited 2024 Aug 8]; Available from: http://www.jcdr.net/article\_fulltext.asp?issn=0973-709x&year=2013&month=January&volume=7&issue=1&page=156-157&id=2694
- 107. Walton SF, Currie BJ. Problems in Diagnosing Scabies, a Global Disease in Human and Animal Populations. Clin Microbiol Rev. 2007 Apr;20(2):268–79.
- 108. Richards RN. Scabies: Diagnostic and Therapeutic Update. J Cutan Med Surg. 2021 Jan;25(1):95–101.